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ABSTRACT 
Characterization of the Protein-Protein Interactions between Histone 
Methyltransferase DOT1L and MLL Fusion Proteins towards Developing 
Small Molecule Inhibitors 
by 
Chenxi Shen 
 
Chair: Zaneta Nikolovska-Coleska 
 
The MLL fusion proteins activate target genes in part via recruitment of DOT1L 
(disruptor of telomeric silencing 1-like), a unique histone H3 lysine 79 (H3K79) 
methyltransferase. The resulting hypermethylation of H3K79 at the Hox and 
MEIS1 loci is a pivotal event for leukemogenesis in acute leukemia, suggesting 
that the protein-protein interactions (PPI) between DOT1L and MLL oncogenic 
fusion proteins represent a potential therapeutic target. We have initiated efforts 
in this direction by detailed biochemical and functional characterization of the PPI 
between DOT1L and the MLL fusion proteins, AF9 and ENL. We determined that 
full length DOT1L protein binds to AF9 and ENL with Kd of 33nM and 206nM 
respectively. The binding site in DOT1L was mapped and found that only 10 
 xvii 
 
amino acids in DOT1L are involved in the interaction with AF9 or ENL. The 
identified DOT1L 10mer peptide directly binds to the AF9/ENL C-terminal domain. 
Alanine scanning mutagenesis studies of DOT1L 10mer peptide demonstrated 
that four conserved hydrophobic residues are important for the binding to 
AF9/ENL. We also found that phosphorylation of Serine 868 in human DOT1L 
abolished AF9/ENL-DOT1L interaction significantly. To examine the critical role 
of the DOT1L-AF9 interaction in transformation by MLL fusion protein, we 
performed a colony forming unit (CFU) assay using MLL-AF9 transformed cells 
lacking endogenous DOT1L. While introduction of the wild type DOT1L construct 
can restore CFU formation, the DOT1L construct lacking the 10 amino acids was 
unable to rescue the colony forming potential of the MLL-immortalized cells. 
These results demonstrate that PPI of DOT1L with AF9/ENL is required for 
transformation of MLL-AF9 and suggest that disruption of this PPI is a promising 
therapeutic strategy for MLL-fusion protein associated leukemia. Based on these 
studies, we employed high-throughput screening (HTS) approach for the 
discovery of inhibitors targeting DOT1L recruitment by MLL-fusion proteins. For 
this purpose we developed and optimized a quantitative, reliable fluorescence 
polarization (FP) based binding assay (Z‟ factor of 0.72) using AF9 protein and 
fluorescein-labeled DOT1L 10mer peptide. With the optimized FP assay, HTS of 
approximately 101,000 compounds was performed for identification of small 
molecule inhibitors and 39 compounds demonstrated dose-dependent inhibition. 
The analysis of the chemical structures of these 39 compounds showed that they 
can be classified into five clusters with different chemical scaffolds and the rest of 
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the compounds have unique structures (Figure 3.10). Using our FP assay along 
with surface plasmon resonance (SPR) and STD NMR based secondary assays, 
four compounds were confirmed with IC50 values ranging from 10 – 50 µM. In 
summary, we confirmed the requirement for DOT1L recruitment by MLL fusion 
proteins in leukemogenesis, mapped the AF9 and ENL binding site in DOT1L 
protein necessary for the PPI and demonstrated the feasibility of development of 
small molecules targeting the C-terminal hydrophobic domain in AF9 and ENL, 
indicating it is a “druggable” target. Our work has laid the foundation for further 
development of both peptidomimetics and small-molecule inhibitors of the 
DOT1L/MLL fusion protein interaction. Such inhibitors can serve as both 
chemical tools for investigation of the role of this interaction in leukemogenesis 
and normal hematopoiesis and as lead compounds for the development of a new 
class of potential anticancer therapeutics.  
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Chapter 1  
Introduction 
1.1 Epigenetics and histone methylation 
1.1.1 Epigenetics 
Epigenetics is the study of the mechanisms underlying inheritable 
phenotypic variations caused by sequence-independent DNA alterations. These 
changes include DNA methylation, small, non-coding RNAs and histone 
modifications [1]. Post-translational modification of histones provides an 
important regulatory platform for processes such as gene transcription and repair 
of DNA damage. Different covalent post-translational histone modifications 
generate a myriad combination of histone marks, which collectively are termed 
the „histone code‟ [2, 3] and include “marks” such as phosphorylation (P), 
acetylation (Ac), methylation  (Me) and ubiquitination (Ub) [4-6].  
Post-translational modification of histones is a dynamic and reversible 
process regulated by various histone-modifying enzymes, known as „writers‟ and 
„erasers‟. The writers are enzymes that catalyze chemical modifications of 
histones in a residue-specific manner. Examples include histone 
methyltransferase and histone acetyltransferase. Erasers are enzymes that 
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remove chemical modifications from histones, for example, histone demethylase 
(HDMT) which removes methylation marks and histone deacetylase (HDAC) 
which removes histone acetylation modifications [2, 3].  
The „reader‟ proteins bind specifically to a certain type or combination of 
histone modifications and translate the histone code into a meaningful biological 
outcome, whether transcriptional activation, silencing or other cellular response 
[7]. Histone readers possess motifs that are capable of specifically interacting 
with the modified histones. For example, the reader bromodomain can recognize 
acetylated lysine and plant homeodomain (PHD) finger and chromodomain bind 
methylated lysine. 
Emerging evidence indicates that misregulation of histone modification, 
caused by deregulation of these histone „writers‟, „erasers‟ or „readers‟, 
contributes to the initiation and progression of human cancers [8] and these 
epigenetic players might be potential targets for therapeutic intervention. Clinical 
success of histone deacetylase inhibitors in cutaneous T cell lymphoma and DNA 
demethylating agents in myelodysplastic syndrome offers a compelling argument 
for therapeutic intervention of epigenetic players in the treatment of cancer. The 
pharmacological doses of an HDAC inhibitor, all-trans-retinoic acid, induces 
relatively specific effects on histone H3 acetylation in PML-RAR α-fusion-positive 
acute promyelocytic leukemia cells (PML), and the H3 acetylation of the histone 
underlies both differentiation therapy and epigenetic therapy of PML [9, 10] 
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1.1.2 Histone methytransferases 
Histone methylation is a chemical modification involving the addition of 
one (mono), two (di) or three (tri) methyl groups to lysine or arginine residues in a 
histone protein [4] and it is one of the most studied post transcription 
modifications. Within histones, methylation has been observed at multiple lysine 
sites, including K4 of histone H3 (H3K4), and H3K9, H3K27, H3K36, H3K79, and 
H4K20. In general, methylation at H3K9, H3K27, and H4K20 correlates with 
repression of transcription, while methylation at H3K4, H3K36, and H3K79 
correlates with activation of gene transcription [11-13]. Histone 
methyltransferases (HMTase), the writers responsible for adding the methyl 
marks to histones, include lysine methyltransferases and arginine 
methyltransferases. Lysine methyltransferase can be classified based on the 
presence or absence of the evolutionarily conserved SET domain, named after 
Drosophila Su(var)3-9 (Suppressor of Variegation 3-9), E(z) (Enhancer of Zeste), 
and Trithorax [14]. The mixed lineage leukemia (MLL) family of histone 
methyltransferases are typical SET domain lysine methyltransferases, which 
methylate H3K4 [15], while Disruptor of telomeric silencing 1 like (DOT1L) is an 
non-SET domain lysine methyltransferase, responsible for H3K79 methylation 
[16]. 
Histone methyltransferases are known to play important roles in many 
biological processes, including cell-cycle regulation, DNA damage [17] and stress 
response, development and differentiation [18, 19]. Establishment of an 
appropriate pattern of histone methylation is not only crucial for normal 
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Figure 1.1 Structure of catalytic domain of DOT1L 
protein (PDB ID: 1WN3). The N-terminal region (aa 1-
126) is colored yellow, the open α/β structure (aa 141-332) 
is shown in cyan, and the loop L-EF connecting the two 
regions is shown in red. The bound SAM molecule is 
shown in a ball-and-stick model (carbon, gray; nitrogen, 
blue; oxygen, red; sulfur, yellow).  
development and differentiation, but is also intimately associated with tumor 
initiation and development [4, 20]. 
 
1.2 Disruptor of telomeric silencing 1 like (DOT1L), a histone 
methyltransferase  
1.2.1 DOT1L is a unique histone methyltransferase 
DOT1L is a novel histone methyltransferase that was first identified in 
yeast by its ability to 
dysregulate gene 
silencing in the vicinity of 
telomeres [21]. It is the 
mammalian counterpart 
of yeast Dot1 and 
currently the only 
identified histone 3 
lysine 79 (H3K79) 
methyltransferase [16, 
22]. It is distinct from 
other histone lysine methyltransferases in several ways: 1) DOT1L does not 
contain the evolutionarily conserved SET domain [23] and is structurally more 
similar to arginine methyltransferases; 2) it methylates histone H3 lysine 79 
(H3K79), which is in a globular domain located on the nucleosome surface and is 
accessible to the chromatin binding factors; 3) it is capable of introducing  mono-, 
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di-, and tri-methylation of histone H3K79 in a nonprocessive manner, which 
means that after each methylation, DOT1L must dissociate and re-associate with 
K79 to allow cofactor exchange and formation of higher levels of methylation [16, 
24]. The enzymatic domain of DOT1L is located on the N-terminus of the protein 
and the crystal structure of the catalytic domain has been solved [16] (Figure 1.1). 
Generally, the structure of the catalytic domain is composed of α helical domain 
of an open α/β structure, including a 7-stranded β sheet. DOT1L belongs to the 
class I S-adenosyl methionine (SAM)-dependent methyltransferases. The 
catalytic domain of DOT1L and has resemblance with a variety of classical 
methyltransferase, for example, the catechol O-methyltransferase (COMPT) 
(PDB 1VID) [16, 25] In the catalytic domain, there is SAM-binding pocket in 
proximity to a potential lysine-binding channel and a positively charged, flexible 
region which is required for nucleosome binding and enzymatic activity of the 
catalytic domain (Figure 1.1). The C-terminus of DOT1L outside the catalytic 
domain is involved in protein-protein interactions and it has been reported that 
DOT1L interacts with AF9/ENL, AF10 and RNA pol II through the C-terminus 
(Figure. 2.2). These interactions are important for the role of DOT1L in 
transcription activation and elongation [26-29], which are in details discussed in 
Chapter 2. 
1.2.2 Role of DOT1L in diverse biological processes 
DOT1L has diverse biological functions and plays critical roles in multiple 
biological processes. In addition to its participation in telomere silencing, 
genome-wide localization studies revealed that H3K79 methylation is enriched in 
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gene coding regions [30]. DOT1L preferentially occupies the proximal transcribed 
region of active genes, and is correlated with enrichment of H3K79 di- and tri-
methylation [31, 32], implicating a potential role for DOT1L in regulation of 
transcription. Involvement of DOT1L in transcriptional elongation is supported by 
fact that DOT1L is associated with proteins with transcription activation and 
elongation capabilities. The first DOT1L-associated complex, named the ENL-
associated proteins (EAP) complex, was purified by immunoprecipitation using 
antibodies against ENL [26]. The complex contains DOT1L, p-TEFb, AF4, 
AF5q31, LAF4, Ring1, CBX8 and BCoR [26, 33]. p-TEFb is a cyclin-dependent 
kinase complex that phosphorylates Ser2 in the RNA Pol II C-terminal domain 
(CTD). This phosphorylation event is required for the transition of RNA pol II from 
the transcription initiation to the transcription elongation phase. The EAP 
complex possesses both H3K79 methyltransferase and RNA Pol II CTD kinase 
activities. Knockdown of ENL reduced the genome-wide H3K79 me2 level as well 
as the global transcriptional elongation activity, suggesting a link between H3K79 
methylation and transcriptional elongation. Other evidence indicating the role of 
DOT1L in transcription is the functional link between DOT1L and phosphorylated 
RNA Pol II. It has been reported that DOT1L directly interacts with the 
phosphorylated RNA Pol II CTD [29]. Genome-wide profiling analysis indicates 
that the occupancy of DOT1L largely overlaps with that of RNA Pol II at actively 
transcribed genes, especially surrounding transcriptional start sites. 
Transcriptional activation by DOT1L-mediated H3K79 methylation is also 
exploited in leukemia stem cells by chromosomal rearrangements. DOT1L is 
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involved in the pathobiology of mixed lineage leukemia (MLL), which is 
characterized by chromosomal translocations involving the MLL gene. 
Misregulation of DOT1L occurs because components of the elongation 
complexes EAP, SEC and AEP interact with DOT1L and are frequent 
translocation partners of MLL. These oncogenic fusion proteins recruit DOT1L to 
ectopic loci whose mis-expression contributes to the transformed phenotype. The 
important role of DOT1L in MLL will be discussed in detail in the following 
sections. 
Mammalian DOT1L is an essential gene that is required for 
embryogenesis and hematopoiesis [34, 35]. Dot1L-deficient embryos show 
multiple developmental abnormalities, including growth impairments, 
angiogenesis defects in the yolk sac, and cardiac dilation, and die 9.5 - 10.5 days 
post coitum. Embryonic stem (ES) cells from Dot1L mutant blastocysts show 
global loss of H3K79 methylation capability and reduced levels of 
heterochromatic marks (H3K9 di-methylation and H4K20 tri-methylation) at 
centromeres and telomeres, changes which are accompanied by aneuploidy, 
telomere elongation, and proliferation defects.  
The cardiovascular defect observed in mDOT1L knockout embryos [35] 
suggested that mDOT1L may play a role in cardiac development, which is 
consistent with ex vivo studies demonstrating a correlation between increased 
H3K79 methylation and an induced expression of cardiovascular marker genes 
during myocardiogenesis [36]. A cardiac-specific knockout mouse model was 
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generated to elucidate the role of mDOT1L in cardiac development and function 
[37]. This cardiac-specific knockout of mDOT1L caused dilated cardiomyopathy 
(DCM), which indicated that DOT1L plays an important role in cardiac function.  
DOT1L function is also vital for hematopoiesis.  In a mouse line, in which a 
gene trap has been used to abrogate DOT1L activity [38], the embryonic lethality 
occurred at mid-gestation in Dot1L-deficient mice. A defect in early erythropoiesis 
is a primary contributor to this embryonic lethality. Gene expression in 
hematopoietic progenitor cells of these embryos indicated that GATA2 and PU.1 
are genes critical for early hematopoietic fate decisions. The down-regulation of 
Gata2 in Dot1L-deficient hematopoietic cells caused de-repression of the myeloid 
transcription factor PU.1 which blocks erythroid differentiation. 
Taken together, all these studies show that DOT1L is vital to development 
and its role under normal cellular conditions as well as transformed conditions is 
emerging and attracting more attention. 
 
1.3 Mixed lineage leukemia (MLL) 
1.3.1 Wild type MLL and MLL fusion protein  
MLL is a particularly aggressive hematopoietic malignancy that occurs 
predominately in pediatric patients. MLL gene rearrangements are present in 
over 70% of infant leukemias [39] and in general account for approximately 5% of 
acute lymphoblastic leukemia (ALL), 5-10% of acute myeloid leukemia (AML), 
and a significant portion of mixed lineage leukemia (MLL) cases [40]. 
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Furthermore, almost all secondary leukemias associated with exposure to 
topoisomerase II targeting drugs involve chromosome translocation at 11q23 [41]. 
Translocation of the MLL gene on chromosome 11q23 is recognized as 
one of the typical characteristics of MLL. MLL gene rearrangements generate a 
large variety of oncogenic MLL fusion proteins. In 2010, 66 MLL fusion proteins 
have been identified (http://atlasgeneticsoncology.org/ Genes/MLL.html). Most of 
the common MLL fusion proteins are nuclear proteins with transcriptional 
activating activity [42-44]. The most common translocations in ALL are t(11;19) 
and t(4;11), resulting in the fusion proteins MLL-ENL and MLL-AF4, respectively. 
In contrast, the t(9;11) translocation, resulting in the MLL-AF9 fusion protein, is 
more frequently found in AML [42]. In addition to the nuclear translocation 
partners, another class of MLL fusion partners consists of cytoplasmic proteins 
that contain dimerization domains, such as AF6. Dimerization of these MLL 
fusion proteins leads to potent transcriptional activation and is essential for their 
leukemogenic capacity [45, 46]. The MLL gene is approximately 89kb long, 
consisting of 37 exons [47] and encodes a 3968 amino acid nuclear protein with 
a complex domain structure. A summary of the wild type MLL protein domain 
structure is presented in Figure 1.2, and has been described thoroughly in 
several reviews [15, 42]. Briefly, MLL contains three short AT-hook motifs on the 
N-terminal region, and these mediate binding to the minor groove of AT-rich 
genomic DNA sequences [48]. There are two nuclear localization sites (SNL1 
and SNL2) immediately adjacent, on the C-terminal side of the AT-hooks that are 
followed by a DNA methyltransferase (DMT) homology domain that includes a 
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Figure 1.2 Schematic of wild type MLL and MLL-rearranged fusion proteins.  
Major functional domains and the proteolytic cleavage site associated with wild-
type MLL are indicated. MLL fusion proteins consist of the N-terminus of wild-type 
MLL (up to the breakpoint region) fused in a frame with a translocation partner 
such as AF9, ENL and AF4, or a cytoplasmic protein, such as AF6. 
 
CxxC zinc-finger motif [49, 50]. There are several PHD (Plant Homology) fingers 
in MLL [51]. The C-terminus SET domain possesses histone H3 lysine 4 (H3K4) 
methyltransferase activity [52, 53] and is structurally homologous to Drosophila 
melanogaster trithorax. The MLL protein is cleaved by an aspartic protease 
named taspase into an N-terminal fragment (MLLN) and a C-terminal subunit 
(MLLC) [54, 55]. The MLLN fragment contains several functional regions that are 
considered essential for correct localization of the MLL complex.  
The MLLN portion binds to a large number of different proteins. Menin 
(MEN1) and lens-epthelium-derived growth factor (LEDGF) are two of the 
proteins interact with MLLN and are found to be essential for the recruitment of 
wild type MLL and MLL fusion proteins to gene targets. Direct interactions 
between Menin and the extreme N-terminus of MLL are essential for MLL-
rearranged leukemogenesis [56, 57]. The MLLC subunit associates with several 
proteins, including MOF, WDR5, ASH2L and RBBP5, to modify chromatin 
structure, thereby facilitating transcription activation [58, 59].  All identified MLL 
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fusions contain the first 8-13 exons of MLL and a variable number of exons from 
fusion partner genes [60]. The breakpoint region in MLL is immediately next to 
the CxxC domain, with deletion of the distal C-terminal SET domains and in-
frame fusion to one of many different translocation partners (Figure 1.2). The 
AF4 and ENL protein families are the most frequent MLL fusion partners, 
accounting for two thirds of MLL associated leukemias [40]. MLL gene 
rearrangements create fusion genes that contain the 5‟ portion of MLL and the 3‟ 
portion of its fusion partner. Those fused gene products cause the sustained 
expression of MLL target genes, for example, Hox genes and consequent 
enhanced proliferation of hematopoietic progenitors. However, the mechanisms 
by which the major fusion partners contribute to MLL-rearranged 
leukemogenesisare only beginning to be defined. 
Although MLL fusion proteins have incredible diversity, they have several 
features in common. First, all the MLL fusion proteins share a common structure 
with the respective partners invariably fused in a frame to MLLN right after the 
CxxC domain but excluding the PHD fingers. Second, all the MLL fusion proteins 
can be divided into two classes, the nuclear proteins, which include AF4, AF9, 
ENL, AF10 and ELL, and the cytoplasmic proteins, such as AF6, GAS17 and 
AP1.  
The molecular pathways of the nuclear MLL fusion proteins include 
histone lysine methylation, acetylation and arginine methylation and involve 
transcriptional elongation and chromatin modification. The most frequent nuclear 
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fusion partners of the ENL and AF4 family are members of the EAP complex that 
combines histone H3K79 methyltransferase activity catalyzed by DOT1L with 
transcriptional elongation stimulation by pTEFb (positive transcription elongation 
factor b, which is composed of catalytic subunit Cdk9 and a regulatory subunit, 
cyclin T). The EAP complex phosphorylates the C-terminal repeat domain of 
RNA polymerase II. It is speculated that recruitment of one or more of these 
complexes and introduction of histone lysine methylation by chimeric MLL fusion 
proteins facilitates sustained expression of MLL-target genes, resulting in 
leukemic transformation. 
In addition to lysine methylation, recent studies have also indicated that 
fusions of MLL regulate its target gene expression through histone arginine 
methylation [61, 62]. MLL-EEN was found to recruit histone H4 arginine 3-
methyltransferase (PRMT1) through the adaptor protein SAM68. Additionally, this 
modification has been shown to be correlated with an increased histone 
acetylation, suggesting cross talk in the MLL molecular mechanism between 
acetylation and arginine methylation. 
Fusions of MLL with the histone acetyltransferases CREB binding protein 
(CBP) and the related p300 have also been observed [63-65]. Structure function 
analyses clearly singled out the bromo- and histoneacetyltransferase domains of 
CBP as necessary and sufficient for the oncogenic function of the respective 
fusion proteins.  
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Table 1.1 Immunoprecipitation complexes of MLL fusion protein complexes 
Complex Components Ref. 
EAP ENL, AF4, p-TEFb, DOT1L, AF9, 
AF5q31, CBX8, BCoR, HSP70, 
RING1 
[26] 
AEP ENL, AF9, AF4, p-TEFb, AF5q31 [44] 
SEC ENL, AF4, p-TEFb, AF9, AF5q31, 
ELL1, ELL2, ELL3 
[70] 
DotCom ENL, DOT1L, AF9, AF10, AF17, 
TRRAP, SKP1, β-Catenin 
[68] 
 
Unlike nuclear proteins, the cytoplasmatic MLL fusion proteins, including 
AF6, GAS17 and AFp1, employ different mechanisms for the leukemogenic 
transformation. Studies indicate that cytoplasmatic MLL fusion proteins dimerize 
via coiled-coil or other dimerization domains provided by the fusion partners. The 
dimerization plays an important role in these MLL transformed leukemias [45, 46]. 
However, the mechanism by which dimerization of the fusion protein activates 
the target gene has not been delineated. 
1.3.2 DOT1L and MLL fusion proteins 
Although the leukemogenic mechanisms underlying MLL fusion forms are 
poorly understood, recent studies have begun to unveil a common transformation 
pathway for the most common MLL fusion forms. DOT1L was revealed to be a 
very important protein involved in MLL transformed leukemia.  
Aberrant induction of H3K79me was observed in leukemia-promoting 
oncogenes, such as Hoxa9, in leukemia cells transformed by MLL-AF9, MLL-
ENL, MLL-AF4 and, MLL-AF10, which represent the most common MLL fusion 
forms. It has been reported that MLL-ENL, MLL AF9, MLL-AF10 and CALM-
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AF10 fusions recruit DOTL directly. Mutations of MLL-ENL, MLL-AF9 or MLL-
AF10 that disrupt the interactions with DOT1L also abolish leukemia 
transformation [26, 28, 44]. Recent biochemical studies have further revealed 
that DOT1L actually associates itself with a long list of factors that are known 
MLL fusion partners. These include ENL [26, 44, 66], AF9 [66, 67], AF10 [28, 68], 
AF17[68], AF4 (also known as MLLT2 or AFF1) [26, 69], AF5q31 (also known as 
MCEF or AFF4) [26] and LAF4 [26]. These MLL fusion proteins associate directly 
or indirectly with DOT1L and form multiple protein complexes. As summarized in 
Table 1.1, the reported MLL fusion protein complexes include the ENL 
associated protein complex (EAP) containing ENL, AF4, DOT1L and pTEFb [26];  
the super  elongation  complex  (SEC), containing AF4, AF9, ENL, AFF4, ELL1 
and pTEFb [70], AEP (containing AF4, AF5, ENL and pTEFb) [44], and DotCom 
(containing DOT1L, AF9, ENL, AF10, AF17 along with several Wnt signaling 
pathway components) [68]. AF9, ENL, AF10 and AF17 were identified as stable 
components of DOT1L-containing complexes [68].  
In an intriguing model, DOT1L is responsible for aberrant transcription in 
many MLL fusion-induced leukemias. AF9 and ENL are the shared components 
of the above complexes [26, 44, 68, 70] and they can interact directly with 
DOT1L. DOT1L-AF10-ENL/AF9 complexes are also further associated via a 
protein-protein interaction network, with a transcription elongation-promoting 
complex, AEP/EAP (which contains AF4, AF5q31, ENL and p-TEFb). Together 
with DOT1L, recruitment of p-TEFb transcription elongation complexes promotes 
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Figure 1.3 Putative model of DOT1L recruitment by MLL fusion proteins. A. 
MLL-AF9/ENL fusion protein can exist in a complex either with DOT1L or with 
AF4/AFF4. Association of AEP leads to phosphorylation and transcription elongation 
of RNA Pol II, and direct recruitment of DOT1L by MLL-AF9/ENL, introducing H3K79 
methylation. B. MLL-AF4 fusion proteins can recruit pTEFb for RNA Pol ll 
phosphorylation and transcription elongation. However, since AF4 does not interact 
with DOT1L directly, recruitment of DOT1L by MLL-AF4 might through an indirect 
protein-protein interaction, e.g. pTEFb. C. In MLL-AF10 transformed leukemia, MLL-
AF10 interacts directly with DOT1L and recruits DOT1L for downstream gene 
transcription. 
the transcription of downstream targets such as Hox genes. These putative 
mechanism models of various MLL fusion protein complexes are illustrated 
schematically in Figure 1.3.  
One of the common features of MLL-transformed leukemias is the 
involvement of transcription initiation and elongation factor pTEFb and histone 
H3K79 metyltransferase DOT1L. In MLL-ENL, the MLL-AF9/ENL fusion protein 
can exist in a complex either with DOT1L or with AF4/AFF4. Association of AEP 
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leads to RNA Pol II phosphorylation and transcription elongation, and direct 
recruitment of DOT1L by MLL-AF9/ENL leading to H3K79 methylation. MLL-AF4 
fusion proteins can recruit pTEFb for RNA Pol ll phosphorylation and 
transcription elongation but since AF4 does not interact with DOT1L directly, 
recruitment of DOT1L by MLL-AF4 might proceed through indirect protein-protein 
interactions. In this connection, it has been reported that DOT1L interacts with 
the phosphorylated RNA Pol II CTD [29], which might be a bridge for recruitment 
of DOT1L by MLL-AF4. In MLL-AF10 transformed leukemia, MLL-AF10 interacts 
directly with DOT1L and recruitment of DOT1L for downstream gene transcription 
[28]. 
1.3.3 Hox genes are crucial downstream targets of MLL 
The clustered homeobox (Hox) genes have been identified as targets of 
mammalian MLL [71-73]. In humans, a total of 39 Hox genes have been 
identified. They are linked in four separate clusters, Hoxa, Hoxb, Hoxc and Hoxd, 
located on chromosomes 7, 17, 12 and 2, respectively [74]. Based on sequence 
similarities and their positions within the clusters, they are further classified into 
13 groups laid out from position 1 to 13 in a 3‟-5‟ direction [75, 76].  HOX proteins 
constitute a particular subgroup of homeodomain transcription factors that serve 
critical functions in embryonic development [72] and normal hematopoietic 
differentiation [77, 78]. The A cluster Hox genes, including Hoxa7 and Hoxa9 and 
the Hox cofactor Meis1, are normally involved in early hematopoietic stem cells 
[79]. Hoxa9 is an important regulator of hematopoiesis and acts, in part, by 
promoting stem-cell renewal [80]. The deregulation of Hox genes appears to be 
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the most crucial factor for MLL fusion-induced leukemogenesis [81, 82]. 
Conditionally transforming this version of MLL–ENL shows that the expression of 
Hoxa9 and Meis1 can replace the gain-of-function activity of the fusion proteins, 
indicating that these are crucial MLL fusion protein targets [81]. Additionally, 
retroviral transformation assays show convincingly that MLL-ENL transformation 
requires functional Hoxa7 and Hoxa9 [83]. 
 
1.4 DOT1L is a validated target in MLL  
1.4.1 Role of DOT1L in MLL 
Transcriptional activation by MLL fusion proteins is accompanied by a 
dramatic increase of histone H3 lysine 79 (H3K79) methylation levels at the 
prominent MLL-fusion downstream target loci Hoxa9 and Meis1 in MLL-ENL 
transformed hematopoietic progenitors [84]. Subsequent genome-wide analysis 
revealed a distinct pattern of H3K79 methylation in an MLL–AF4 mouse model, 
and in human MLL-rearranged primary leukemia samples when compared to 
normal proB cells and leukemias with other cytogenetic abnormalities [85]. This 
link was further strengthened by analysis of H3K79 methylation patterns on MLL–
AF4 direct target loci in a human MLL-rearranged leukemia cell line, and MLL–
AF9 direct targets in a mouse model [86, 87]. All this evidence indicated that 
MLL-fusion target genes are associated with histones methylated at H3K79, and 
H3K79 methylation patterns on MLL–AF9 target loci appear abnormal [87]. Since 
DOT1L is the only known histone methyltransferase that is capable of introducing 
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H3K79 methylation, the role of DOT1L in MLL transformed leukemia was studied 
extensively. In recent years, several groups have used shRNA-knockdown, or 
conditional knockout models to confirm that DOT1L is required for MLL-fusion-
mediated leukemic transformation, and in vivo leukemia development and 
maintenance [34, 87-90]. 
Analysis  of  H3K79 methylation  profiles  and  gene-expression changes  
after  loss  of  DOT1L  in  MLL–AF9 driven leukemia cells revealed that only a 
small subset of genes demonstrate a change in expression shortly after DOT1L 
inactivation. However, this set of genes is highly enriched for MLL–AF9 targets 
and other genes with known functional significance in MLL-rearranged leukemia 
biology [87]. It appears that functional DOT1L is required for the most common 
MLL-rearranged leukemias, and displays specificity with respect to several other 
types of leukemia. 
MLL fusions are potent oncogenes and they alter gene expression in 
hematopoietic cells through interactions with DOT1L. The MLL-ENL or MLL-AF9 
interaction with DOT1L is critical in the transformation capability of the fusion 
protein, since deletion or mutations in the AF9 or ENL C-terminal domain, which 
is necessary for DOT1L interaction, eliminates the transformation capability of 
MLL fusion protein [26, 27]. Additionally, transient knockdown of ENL diminished 
genome-wide as well as HOXA9 gene-speciﬁc H3K79 dimethylation, providing 
further circumstantial evidence of a critical role for the ENL - DOT1L interaction in 
leukemia related to MLL-ENL [26].  
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DOT1L is involved in transformation by other MLL fusion proteins In 
addition to MLL-AF9 and MLL-ENL. These include MLL-AF4 [85], MLL-AF10 [28] 
and MLL-AF6 [91]. In MLL-AF10 transformed leukemia, both MLL-AF10 and 
H3K79 methylation were specifically enriched at the Hoxa9 locus in MLL-AF10 
transformed cells. The transformation capability of MLL-AF10 was dependent on 
DOT1L enzymatic activity and recruitment of DOT1L by interaction with MLL-
AF10 is important for MLL-AF10 leukemia, since disruption of the interaction 
between MLL-AF10 and DOT1L abolished the MLL-AF10 transformation [28]. 
Although there is no evidence indicating the direct interaction between DOT1L 
and MLL-AF4 or MLL-AF6, there is a link between DOT1L and these MLL fusion 
proteins since knockdown of DOT1L significantly interferes with MLL-AF4 
induced transformation and also with the activation of Hox genes [85]. Targeted 
disruption of Dot1l using a conditional knockout mouse model also inhibited 
leukemogenesis mediated by the MLL-AF6 fusion oncogene [91]. 
It is clear that DOT1L is broadly involved in leukemiogenesis, particularly 
when mediated by MLL fusion proteins. However, the exact mechanism 
underlying the contribution of DOT1L to the leukemogenic gene activation 
process requires further elucidation. DOT1L has been associated with protein 
complexes with transcription elongation activities [26, 27, 69] and evidence that 
DOT1L associates with MLL fusion partners [26, 67, 69, 73, 92] might help to 
elucidate how DOT1L is involved in MLL hematological malignancy. The 
discovery of DOT1L related complexes such as EAP, DotCom, or AEP (Table 
1.1), prompted the hypothesis that members of the complex, when fused to MLL, 
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misguided DOT1L and pTEFb to MLL target loci. DOT1L would then presumably 
methylate H3K79 to induce an open chromatin formation, and pTEFb would 
stimulate RNA Pol II to transcribe the respective locus. DOT1L and pTEFb 
appear to be the „effector units‟ of these complexes. A suggested general 
mechanism by which DOT1L contributes to the leukemogenesis process is 
shown in Figure 1.3 and can be described as interaction between DOT1L and 
MLL fusion partners leading to mistargeting of DOT1L to the gene targets of MLL 
fusion proteins, such as the Hoxa cluster and Meis1. Aberrant hypermethylation 
of H3K79 leads to constitutive transcriptional activation of these genes, which in 
turn results in leukemic transformation.  
1.4.2 Rationale and strategies for targeting DOT1L functions 
The crucial role for DOT1L in MLL-rearranged leukemias is now well 
established and is strongly supported by functional evidence demonstrating that 
a loss of DOT1L profoundly affects the leukemogenic gene expression program 
and leukemogenic activity of MLL fusion-transformed cells, while several non-
MLL leukemia cells are unaffected [85]. The development of small molecule 
inhibitors for DOT1L is clearly warranted because such molecules will help to 
address some of the outstanding mechanistic questions, and most importantly, 
they may change the outlook for patients with this devastating type of leukemia.  
A critical step in transformation and disease progression in MLL is the 
aberrant recruitment of DOT1L by MLL fusion proteins. Two plausible strategies 
for therapies against DOT1L-related leukemia are: 1) specifically targeting the 
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enzymatic activity of DOT1L in transformed cells; and 2) blocking the protein-
protein interactions between DOT1L and oncogenic fusion proteins. The recent 
development [88] of a DOT1L enzymatic inhibitor, a small molecule inhibitor, 
EPZ004777 which competes with S-adenosyl methionine, provided proof of 
principle for the development of DOT1L enzymatic activity inhibitors as targeted 
therapeutics for MLL-rearranged leukemia. Treatment of MLL cells with 
EPZ004777 selectively inhibits H3K79 methylation and blocks expression of 
leukemogenic genes. Exposure of leukemic cells to EPZ004777 results in 
selective killing of cells bearing the MLL gene translocation, with little effect on 
non-MLL-translocated cells. Additionally, in vivo administration of EPZ004777 
leads to extension of survival in a mouse MLL xenograft model. These results 
provide compelling support for DOT1L inhibition as a basis for targeted 
therapeutics against MLL. However, it is important to note that potential inhibitors 
of DOT1L enzymatic activity must be used with caution since DOT1L is the only 
known H3K79 methyltransferase and is required for survival of normal somatic 
cells. Constitutive and conditional knockout studies of DOT1L, have shown it to 
be essential for embryonic development, prenatal and postnatal hematopoiesis 
and cardiac function [34, 35, 38, 87, 90]. This universal and essential function of 
DOT1L in multiple cell types [93] suggests that direct inhibition of DOT1L histone 
methyltransferase activity might be toxic. Consequently, development of 
therapeutic strategies allowing selective inhibition of DOT1L function is important 
and necessary. The disruption of DOT1L interactions with oncogenic fusion 
proteins is an attractive targeting approach, because 1) recruitment of DOT1L by 
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MLL fusion protein is important for MLL transformation; 2) targeted disruption of 
DOT1L interactions with MLL fusion proteins might be more selective to leukemia 
cells compared to universal inhibition of DOT1L enzymatic activity. 
 
1.5 Summary 
In summary, genetic and biological studies support DOT1L as a bona fide 
drug target for treatment of MLL. Besides the enzymatic function of DOT1L, the 
protein-protein interactions (PPIs) between DOT1L and MLL fusion proteins are 
also interesting potential targeting sites.  
Protein-protein interactions are emerging as promising drug targets and 
reports of PPI inhibitors have increased in the last few years[94]. The first step 
toward development of inhibitors of PPIs is to define the interaction sites and 
residues crucial to the interaction. To date, interactions of MLL fusion protein with 
DOT1L were only observed in Co-IP and yeast two hybrid approaches and there 
is lack of further understanding of this PPI. In this dissertation work, we have 
addressed these key questions regarding MLL fusion protein AF9/ENL and 
DOT1L PPIs. In Chapter 2, we have undertaken the initial steps toward 
characterized the AF9/ENL-DOT1L PPIs, including mapping the interaction site, 
identifying the crucial residues for interaction, and proving that the identified 
interaction site was important for MLL transformation.  In Chapter 3, we applied a 
high-throughput screening (HTS) approach to identify small molecule inhibitors of 
the AF9-DOT1L interaction. Toward this goal, we have developed and optimized 
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fluorescence polarization based binding assays for the AF9-DOT1L interaction. 
The initial HTS for potential inhibitors of the DOT1L-MLL fusion protein 
interaction were performed and the identified hits were further characterized by 
FP and SPR-based assays. Finally in Chapter 4, we discuss the implications of 
these studies and potential future strategies for targeting MLL fusion proteins and 
DOT1L interactions.  
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Chapter 2  
Biological Characterization of MLL fusion proteins and DOT1L 
Protein-Protein Interactions 
2.1 Abstract 
The MLL fusion proteins, AF9 and ENL, activate target genes in part via 
recruitment of the histone methyltransferase DOT1L (Disruptor Of Telomeric 
silencing 1-Like). We have characterized the interaction between DOT1L and the 
MLL-fusion proteins, AF9/ENL. The AF9/ENL binding site in human DOT1L was 
mapped and the interaction site was identified as a 10 amino acid region 
(DOT1L865-874), a region that is highly conserved in DOT1L from a variety of 
species. Alanine scanning mutagenesis analysis shows that four conserved 
hydrophobic residues from the identified binding motif are essential for the 
interactions with AF9/ENL. Phosphorylation of DOT1L serine 868 in the AF9/ENL 
interaction region diminished the protein-protein interaction significantly and 
binding studies demonstrated that the entire intact C-terminal domain of 
AF9/ENL is required for optimal interaction with DOT1L. Functional studies show 
that the AF9/ENL interacting site that was mapped is essential for immortalization 
by MLL-AF9, indicating that DOT1L interaction with MLL-AF9 and its recruitment 
are required for transformation by MLL-AF9. These results strongly suggest that 
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disruption of the interaction between DOT1L and AF9/ENL is a promising 
therapeutic strategy for MLL-fusion protein-associated leukemia with potentially 
fewer adverse effects than enzymatic inhibition of DOT1L.  
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Figure 2.1 The domain structure of AF9/ENL 
protein. AF9/ENL has an N-terminal YEATS 
domain, and a C-terminal hydrophobic domain. 
The proteins interacting with AF9/ENL are 
indicated. 
2.2 Background 
2.2.1 AF9 and ENL proteins were involved in multiple protein-protein 
interactions 
AF9 and ENL, the most common fusion partners in MLL rearrangement 
leukemia [1] belong to the YEATS family of proteins. The AF9/ENL protein 
consists of an N-terminal YEATS domain, a poly-serine and -proline region, and 
a coiled-coil hydrophobic domain at the C-terminus [2] (Figure 2.1). The YEATS 
domain is named after the first proteins, Yaf9, ENL, AF9, Taf14, Sas5, that were 
found to contain this module 
[3]. The primary amino acid 
sequence of the YEATS 
domain is evolutionarily 
conserved from yeast to 
humans and is found in 
proteins belonging to a 
variety of chromatin-
modifying complexes and 
transcription factors [4]. The 
C-terminal domains of AF9 
and ENL share high homology [5] and are reported to be involved in interactions 
with many binding partners with roles in transcription and chromatin modification. 
In addition to the sequence similarity, the C-terminal domain of AF9 or ENL 
shares similar protein-protein interactions. Both AF9 and ENL bind to the mouse 
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or human Polycomb proteins [6] [7, 8] [9-11], AF4 proteins (Srinivasan, Nesbit et 
al. 2004,) BCL-6 co-repressor (BCoR) [12] and DOT1L [13, 14]. ENL also has a 
distinct set of protein-protein interactions and it interacts with another MLL fusion 
partner, ABI-1. However, the ABI-1 interaction region of ENL is not in the C-
terminal domain which is important for MLL transformation. [15]. ENL specifically 
associates with histones H3 and H1 whereas it shows no affinity for H4, H2A. 
The histone binding capacity of ENL is crucially dependent on the YEATS 
domain as N-terminal truncation mutants are unable to interact with histones. 
However, the deletion of C-terminal domain has no influence on H1/H3 affinity [7]. 
ENL was also found to be a subunit of 2 novel SWI/SNF complexes, EBAFa and 
EBAFb, ENL-containing BAFa and BAFb complexes [16].  
The C-terminal hydrophobic domain (also called the ANC homology 
domain) of about 90 amino acids of the AF9 and ENL proteins is retained in MLL 
fusion proteins and has been shown to be crucial for recruitment of DOT1L in 
MLL. Deletion or mutations within this region, which can disrupt the PPIs 
between AF9-DOT1L and ENL-DOT1L are also able to abolish the MLL 
transformation [11, 14]. Additionally, AF9 and ENL are able to recruit and activate 
p-TEFb by recruitment of AF4 family members through the C-terminus domain. 
Disruption of AF9-AF4 interaction results in necrotic cell death in several cell 
lines harboring MLL translocations [17]. 
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Figure 2.2 DOT1L interacting proteins. The DOT1L 
interacting proteins and their interaction site in DOT1L are 
indicated. AF9/ENL interacts with DOT1L in the C-terminal 
region (826-1095) lacking any apparent homology motif. 
The AF10 and AF17 interaction sites are indicated by 
dashed line arrows since their interaction sites in DOT1L 
are  not precisely identified. The phosphorylated CTD of 
RNA Pol II interacts with DOT1L (618-627), which is a 
conserved motif call CTD binding patch. 
2.2.2 Protein-Protein interactions between DOT1L and MLL fusion proteins 
DOT1L is a protein with 1537 amino acids. The N-terminal (1-416) of the 
protein is the catalytic domain [18] (Figure 2.2). The C-terminal region of DOT1L, 
outside the catalytic domain is reported to be involved in multiple protein-protein 
interactions. The reported DOT1L interaction partners include AF9, ENL, AF10, 
AF17 and CTD of RNA Pol II [11, 13, 19-22]. The AF9/ENL-binding domain 
within the DOT1L C-terminus has been identified as being between amino acids 
826 and 1095, a region without any recognizable motif [11, 13].  
The physical interaction of DOT1L with AF9/ENL has been demonstrated 
by co-immunoprecipitation and in vivo experiments [11, 23] but a detailed 
characterization of this 
interaction is currently 
unavailable and the 
exact DOT1L fragment 
involved in the 
interaction with 
AF9/ENL has not been 
identified. We have 
characterized the 
DOT1L-AF9/ENL 
interactions using a collection of biochemical and biophysical methods. Our work, 
described below, establishes the molecular basis of the DOT1L-AF9/ENL 
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interactions and provides the necessary foundation for development of small 
molecule inhibitors targeting this interaction in MLL translocated leukemias. 
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2.3 Experimental procedures 
2.3.1 Plasmids and Cloning 
The full-length hDOT1L was generously provided by Dr. Yi Zhang from the 
University of North Carolina at Chapel Hill. All different DOT1L constructs, tested 
in this study (Table 2.1), were made using full length hDOT1L as a template. The 
plasmids for AF9, ENL and AF4, were made using MLL-AF9, MLL-ENL and MLL-
AF4 fusion proteins as templates. All these constructs for protein expression 
were cloned by ligation independent cloning (LIC) methods as described before 
[24]. Different DOT1L constructs (Table 2.1) and AF4 proteins (749-775) were 
cloned into pMocr-LIC vector obtained from the UM CSB HTP facility. ENL (489-
559) was cloned into pMSCG9-LIC vector and AF9 (497-568) was cloned into 
pGB1-LIC vector. MSCV based HA tagged wild type mouse DOT1L, 
methyltransferase mutant DOT1L (RCR), and neomycin vector constructs have 
been reported before [25]. MSCV-HA-mDOT1L 10aa∆ construct where 10 
residues identified as AF9/ENL interaction site (863-872 aa) were deleted by 
using the QuickChange site-directed mutagenesis kit (Agilent Technologies). 
These residues in mouse are conserved and correspond to the identified human 
DOT1L interaction site, 865-874 aa (Figure 2.5B). ENL L550E mutant was also 
created by site-directed mutagenesis (QuickChange, Agilent Technologies). To 
construct the pCMV-Myc CxxC-AF9 plasmid, a fragment of an MLL-AF9 fusion 
protein was cut from an MLL-AF9 fusion protein expression vector using MfeI 
and XhoI and inserted into the pCMV-Myc vector (Clontech) following digestion 
with EcoR1 and XhoI. A dual nuclear localization signal was inserted into the SfiI 
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site downstream of the Myc tag. The sequence of MLL includes amino acids 
1116 through 1422 and is followed by AF9 sequence including amino acids 479 
through 568. The positive clones for all desired constructs were confirmed by 
DNA sequencing (University of Michigan DNA sequencing core). 
2.3.2 Protein expression and purification 
All recombinant proteins were expressed in Escherichia coli strain BL21 
(DE3) (Invitrogen). The medium for bacterial growth was Luria Broth (for all 
binding studies) and M9 minimal medium supplemented with 15NH4Cl 
(Cambridge Isotope Laboratories) (for HSQC NMR studies). All the proteins were 
induced with 200 µM IPTG at 20 °C except GB1-AF9 (489-497) was induced at 
16 °C. The cells were harvested after 20h and resuspended in cold lysis buffer 
(50 mM Tris HCl, pH 7.5, 150 mM NaCl, 0.01 % β-mercatoethanol) and purified 
by affinity chromatography employing Ni-agarose (Qiagen). Mocr- DOT1L and -
AF4 proteins were further purified by anion exchange chromatography in 25 mM 
Tris HCl pH 7.5, with NaCl gradient ranging from 25 mM to 1 M, and 3 mM DTT, 
while MBP-ENL (489-559), MBP-ENL (489-559) L550E, and GB1-AF9 (497-568) 
proteins were further purified with size exclusion chromatography in 50 mM Tris 
HCl, pH 7.5, 150 mM NaCl, 3 mM DTT. The MBP and Mocr-tags from ENL (489-
559) and AF9 (497-568), respectively, were removed by proteolysis using 
tobacco etch virus (TEV) protease, followed by nickel-NTA column and size 
exclusion chromatography using the same buffer as above to obtain purified 
cleaved proteins. All purified recombinant proteins were stored at -80 °C for 
further experiments. 
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2.3.3 Peptide synthesis 
Peptides were synthesized using standard F-moc solid phase peptide 
synthesis techniques on an ABI 433A automated peptide synthesizer. NovaPEG 
Rink amide resin (EMD) was used to prepare all C-terminal amide-capped 
peptides. Standard side chain protecting groups were used for all amino acids. 
All the peptides were acetylated on the N-terminus. Peptides containing an N-
terminal biotin group or fluorescein were coupled to lysine and two β-alanine 
residues as a spacer. All crude peptides were purified by semi-preparative 
reverse-phase high-performance liquid chromatography (RP-HPLC) and their 
sequence and purity were verified by electrospray ionization mass spectrometry 
(ESI-MS) and analytical RP-HPLC.   
2.3.4 Surface Plasmon Resonance (SPR) binding studies 
All SPR based experiments were performed on a BIAcore 2000 (BIAcore, 
GE Healthcare) instrument. Different tested DOT1L recombinant proteins were 
immobilized on a CM5 sensor chip by standard EDC/NHS coupling chemistry 
followed by ethanolamine deactivation of the surfaces, with immobilization level 
of 2000 to 3000 RU. For immobilization of full length Flag-DOT1L protein, anti-
Flag antibody (Sigma, Anti-FLAG M2) was immobilized on CM5 chip by the same 
amine coupling chemistry. HEK293 whole cells lysate with overexpressed Flag-
DOT1L at 2.4 µg/µl total protein concentration was injected over the Flag 
antibody surface, with immobilized level of 1000RUfollowed by injecting of AF9 
and ENL in different concentrations. For determination of their binding affinity 
AF9 and ENL were tested in concentration from 0.01 to 3 µM in HBS-P buffer (10 
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mM HEPES pH 7.4, 150 mM NaCl, 0.005% v/v P20, GE Healthcare). Injection of 
50 mM NaOH was used to regenerate the proteins bound to the surfaces. The 
Fc1 surface was used as a control surface and was treated in the same manner 
as the active surfaces but in the absence of immobilized protein. Binding 
parameters, kon, koff and Kd were calculated by simultaneous non-linear 
regression using BIAEvaluation software. 
Solution competitive SPR based assay was performed to determine the 
IC50 values of DOT1L peptides.  The tested DOT1L wild type and alanine 
mutated peptides were pre-incubated with AF9 or ENL proteins (500 nM) for at 
least 30 minutes and then the reaction mixture was injected over the surface of 
Mocr-DOT1L (826-1095) immobilized CM5 chip. Response units (RU) were 
measured at 15 seconds in the dissociation phase and the specific binding was 
calculated by subtracting the control surface (Fc1) signal from the surfaces with 
immobilized Mocr-DOT1L. IC50 values were determined by non-linear least 
squares analysis using Graph Pad Prism 5.0 software.  
2.3.5 Fluorescence polarization (FP) assay 
FP experiments were performed in 96-well, black, round-bottom plates 
(Corning) using the plate reader (Biotek H1 hybrid). Fluorescein tagged DOT1L 
10mer peptide (Flu-DOT1L) was used as a fluorescent probe in the FP based 
binding assays. The Kd values of GB1-AF9, MBP-ENL wild type and L550E 
mutated proteins, were determined using a fixed concentration of the tracer (10 
nM Flu-DOT1L) and different concentrations of the tested proteins, in a final 
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volume of 125 µl and assay buffer (100 mM Na2HPO4, pH 7.4, 150 mM NaCl, 
0.01 % Triton X-100 and 4 % DMSO). The plate was mixed on a shaker and 
incubated at room temperature to reach equilibrium. The polarization values in 
milli-polarization units (mP) were measured at an excitation wavelength at 485 
nm and an emission wavelength at 530 nm. Polarization data were analyzed 
using GraphPad Prism 5.0 by non-linear fitting with a one-site binding model.  
AF4 (749-775) protein and several peptides (AF4 14mer, un-labeled and 
biotin-labeled DOT1L 10mer peptide) were tested for their ability to displace the 
Flu-DOT1L from GB1-AF9 protein. The dose-dependent binding experiments 
were carried out in 96-well plates with serial dilutions of tested protein or peptides, 
GB1-AF9 protein (500 nM) and Flu-DOT1L (10 nM) in the same assay buffer and 
final volume of 125 µL. The polarization values were measured after 3h 
incubation. Negative controls containing GB1-AF9 protein and probe (equivalent 
to 0 % inhibition), and positive controls containing only free Flu-DOT1L probe 
(equivalent to 100 % inhibition), were included on each assay plate. IC50 values 
were determined by nonlinear regression fitting of the competition curves 
(GraphPad Prism 5.0).  
2.3.6 Isothermal titration calorimetry 
ITC was carried out using a Nano-ITC Micro Calorimeter (TA Instruments) 
at 20 °C. MBP-ENL (489-559) was dialyzed extensively against 50 mM Na2HPO4, 
(pH 7.5) and 100 mM NaCl, and 80 µM was used for titration studies of DOT1L 
16-mer and 10-mer peptides, and 110 µM for DOT1L 7-mer titration. Tested 
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peptides dissolved in the same buffer at 400 µM (DOT1L 16-mer and 10-mer) or 
500 µM (DOT1L 7-mer) were tested by injecting 2 μl aliquots into the protein 
sample, at time intervals of 30 seconds, to ensure that the titration peak returned 
to the baseline. The ITC data were analyzed by NanoAnalyze software package 
using a one site-binding model. The ITC of MBP-AF9 with DOT1L 16-mer 
peptides was performed on VP-ITC system (MicroCal) at 25 °C. Tested peptides 
were diluted in the same buffer at 300 µM in the presence of 5 % DMSO. The 
peptide was injected in 10 µL aliquots into the protein sample, at time intervals of 
2 minute. The ITC data was analyzed by Origin 7.0 (OriginLab) using a one site-
binding model. 
2.3.7 NMR spectroscopy 
15N-labeled ENL protein sample was prepared in a 50 mM Na2HPO4, pH 
7.5, 50 mM NaCl in 7 % D2O. The binding of DOT1L protein and peptides has 
been characterized by recording 1H, 15N -HSQC spectra of uniformly 15N-labeled 
ENL in the absence and presence of tested protein and peptides in 1:1 molar 
ratio. The presence of tested peptides in solution was confirmed by 1H-1D NMR. 
All spectra were acquired at 30 oC on a Bruker 600 MHz NMR spectrometer 
equipped with a cryogenic probe, processed using Bruker TopSpin and rNMR 
[26], and were analyzed with Sparky [27]. 
2.3.8 Circular dichroism 
DOT1L peptides were dissolved in phosphate buffer (50 mM Na2HPO4, pH 
7.4, 100 mM NaCl). ENL and AF9 protein were dialyzed against the above 
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phosphate buffer overnight. CD measurements were performed at room 
temperature using a Jasco J-715 and a quartz flow cell with a 1 mm path length. 
The spectra were averaged over 10 scans and the baseline (buffer scan) was 
subtracted from each spectrum. The percentage of α helicity was calculated by 
K2D2 online tool. 
2.3.9 Generating the homology model of the complex ENL-DOT1L 
The NMR structure of 2LM0, in which the C-terminal hydrophobic domain 
of AF9 is in complex with the elongation factor AF4, was employed for the 
homology modeling of the complex between ENL and DOT1L. The reported 
NMR structure contains ten conformers and the fourth was randomly selected as 
the template because the alignment of these conformers showed that they are 
virtually identical. The sequence of ENL (489 – 559) was aligned with this 
minimized AF9 – AF4 complex using the program of MOE-align. The homology 
model was built using the Homology Model module of MOE 2010.10. During this 
process, the peptide of LMVKITL was kept as environment for induced fit. In the 
top-scored model produce by MOE, the peptide of LMVKITL was mutated to 
LPISIPL and then the obtained homology model was minimized. 
2.3.10 Cell Culture, Transfections, and Immunoprecipitation 
HEK293 cells were plated in 100 mm culture dishes and cultured in 
Dulbecco‟s modified Eagle‟s medium (DMEM) medium supplemented with 10 %  
FBS and antibiotics. Co-transfection with FLAG-DOT1L and Myc-CxxC-AF9 was 
performed using Lipofectamine 2000 (Invitrogen). Forty eight hours post-
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transfection, cells were collected and lysed using BC-300 lysis buffer: 20 mM 
Tris-HCl pH 8.0, 300 mM KCl, 1 mM EDTA, 10 % glycerol, 0.1 % NP-40 and 
protease inhibitor cocktail (Roche). The lysates was pre-cleared for 2h in Mouse 
IgG Agarose (Sigma-Aldrich). The pre-cleared lysates were incubated with 
different concentrations of DOT1L 10mer peptide at 4 °C overnight. The next day, 
the cell lysates were immunoprecipitated with Anti-FLAG M2 magnetic beads 
(Sigma-Aldrich) at 4 °C for 2h. After incubation, the beads were washed 
extensively, boiled in SDS loading buffer and analyzed by western blotting using 
mouse monoclonal anti-FLAG M2 (Sigma-Aldrich) and goat monoclonal anti-Myc 
tag (Abcam) antibody.  
Primers for and Quantitative PCR (qPCR): 
5S rRNA: TCTACGGCCATACCACCCTGA and 
GCCTACAGCACCCGGTATTCC;  
HA-Dot1l: GCCACCATGTACCCCTACGACGTG and 
GATTTCCTCGCAGACCCACCGGAT 
2.3.11 Pull-down assay 
HEK293 cells transfected with Myc-CxxC-AF9 were lysed in BC-300 lysis 
buffer in the  same way as the Co-IP experiment. The supernatant was pre-
cleared for 2h in streptavidin agarose beads (Thermal Scientific). The pre-cleared 
lysates were incubated with different concentrations of biotin-labeled DOT1L 
10mer peptide at 4 °C overnight. The next day, the cell lysate was incubated with 
streptavidin agarose at 4 °C for 2h. After extensive washing the beads with the 
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BC-300 lysis buffer without NP-40, the pull down samples were applied to SDS-
PAGE electrophoresis and pull-down Myc-CxxC-AF9 protein was probed with 
goat monoclonal anti-Myc tag antibody (Abcam).    
2.3.12 Retroviral Transductions and CFU Assay 
Retroviral production and transduction of bone marrow progenitor cells 
were carried out as described [25]. Briefly, retroviruses were generated by 
transfecting MSCV-HA wild type mouse DOT1L, methyltransferase mutant 
mDOT1L (RCR), mDOT1L deletion (10aa∆; deletion of the residues 863-872 aa) 
constructs, and neomycin vector control into Plat-E cell line with Fugene 6 
(Roche). Fresh viral supernatants were used for transducing MLL-AF9 
transformed cells described [25]. 150,000 cells were used for transduction per 
viral supernatant from 10 cm dish. Cells were then plated on Methocult media 
(Stem Cell Technologies, M3234) with 1% penicillin/ streptomycin (Invitrogen), 10 
ng/ml IL3 (R & D Systems), 5 nM 4-OHT (Sigma) or 100% ethanol, and 1 mg/ml 
G418 (Invitrogen).  Colonies were scored 5-7 days after plating for two rounds.  
In the final round, colonies were stained with 0.1 % p-iodonitrotetrazolium violet 
(Sigma) for visualization.  
2.3.13 RNA extraction, cDNA generation, and Protein extraction 
RNA was extracted from cells using TRIzol Reagent (Invitrogen) and 
converted to cDNA using SuperScript II (Invitrogen) according to manufacturer‟s 
instructions. Whole cell lysate samples were prepared by directly resuspending 
cells in Tris-Glycine SDS sample buffer (Novex) and sonicating for 15 minutes 
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(Bioruptor, Diagenode). Primers for quantitative PCR (qPCR) are provided in the 
supplementary information 
2.3.14 In-gel digestion with trypsin 
Anti-Flag affinity purified DOT1L protein was separated on a SDS-PAGE 
and visualized using Simply Blue Coomassie stain. Protein band corresponding 
to DOT1L was excised and destained with 30 % methanol for 4 h.  Cysteines 
were reduced with 150 µL of 10 mM DTT followed by alkylation with 65 mM 2-
chloroacetamide (in 0.1 M ammonium bicarbonate, pH 8.0) at RT for 30 min, 
each.  Gel slices were crushed, dried using a vacufuge and re-swollen in 30 µL of 
ammonium bicarbonate buffer containing 500 ng of sequencing grade, modified 
trypsin (Promega).  After 45 min incubation on ice, another 40 µL of ammonium 
bicarbonate buffer was added and digestion was carried out at 37 C, overnight.  
Additional 250 ng of trypsin was added 2 h prior to the extraction of peptides.  
Peptides were extracted once each with 150 µL of 60 % acetonitrile/0.1 % TFA 
and acetonitrile/0.1 % TFA.  All extracts were pooled and dried using a vacufuge.  
Sample was re-dissolved in 30 µL of HPLC loading solvent (2 % 
acetonitrile/0.1%TFA) and analyzed immediately. 
2.3.15 Protein identification by LC-tandem MS 
Ten µl of the digest was separated on a reverse phase column (Aquasil 
C18, 15 m tip x 75 m i.d. x 15 cm, Picofrit column, New Objectives, Woburn MS) 
using acetonitrile/1 % acetic acid gradient system (5-60 % acetonitrile over 40 
min followed by 95 % acetonitrile wash for 5 min) at a flow rate of ~300 nl/min.  
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Eluted peptides were directly introduced into an ion-trap mass spectrometer 
(LTQ Orbitrap XL, ThermoFisher) equipped with a nano-spray source.  The mass 
spectrometer was operated in data-dependent acquisition mode to acquire a 
high-resolution full MS scan in Orbitrap analyzer (FWHM 30,000 at 400 m/z) 
followed by collision induced dissociation MS/MS spectrum on the top 9 ions in 
the linear ion-trap (relative collision energy ~35 %).  Dynamic exclusion was set 
to collect 2 MS/MS spectra on each ion and exclude it for further 2 min.  Raw 
files were converted to mzXML format and searched against SwissProt human 
protein database (release 2013) appended with reverse database and common 
contaminants using XTandem with k-score plug-in, an open-source search 
engine developed by the Global Proteome Machine.  Search parameters 
included a precursor peptide mass tolerance of 50 ppm and fragment mass 
tolerance of 0.5 Da.  Oxidation of methionine (+15.9949 Da) and 
carbamidomethylation of cysteines (+57.0214 Da), phosphorylation on S, T and 
Y (+79.966Da) were considered as variable modifications.  Search was restricted 
to tryptic peptides with two missed cleavages.  Tandem outputs were subjected 
to TransProteomic Pipeline (TPP) – A software suite containing PeptideProphet 
[28]and ProteinProphet [29], analysis using default parameters of each program.  
All proteins with a ProteinProphet probability of >0.9 (fdr <2 %) were considered 
for further analysis.  Phosphopeptide matches were manually verified where 
possible. 
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Figure 2.3 Immobilization of Flag-DOT1L for interaction studies. (A) Design of 
the binding experiments. (B) Western Blot of the expression level of transfected Flag-
DOT1L protein. (C) The specificity of immobilizing Flag-DOT1L protein.  
2.4 Results 
2.4.1 Mapping the AF9/ENL binding site in DOT1L  
The interaction of AF9 or ENL with DOT1L has been studied previously by 
co-immunoprecipitation and yeast 2-hybrid studies [10, 14, 23, 30, 31]. To 
understand the molecular basis of DOT1L interaction with MLL-fusion proteins, 
we analyzed these protein-protein interactions (PPIs) using a surface plasma 
resonance (SPR) assay to quantify the binding affinity between full length DOT1L 
protein and MLL-fusion proteins. The flag-tagged full length DOT1L protein was 
transiently transfected in HEK 293 cells. After 48 hours transfection the DOT1L 
protein was captured from the HEK 293 whole cell lysate on an anti-flag 
antibody-coated biosensor chip (Figure 2.3).  
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Figure 2.4 Binding of AF9/ENL protein to DOT1L. (A) and (B) Sensorgrams 
representing the concentration-dependent binding of the C-terminal domain of AF9 and 
ENL tested in a concentration range from 0.01 to 3 µM, with (A) full length Flag-DOT1L 
and (B) Mocr-DOT1L (826 - 1095), both immobilized on a CM5 sensor chip. The kon, koff 
and KD were calculated by simultaneous non-linear regression using a 1:1 binding model 
and BIAevaluation 3.1 software. The experimental data are shown in black while the 
global fit analyses are in red.   
 
The recombinant C-terminal domain from human AF9 (residues 497-568) 
and the corresponding segment from the ENL protein (residues 489-559) (Figure 
2.1) were cloned, expressed and purified for the biochemical binding studies. We 
determined that AF9 and ENL bind to the immobilized full length DOT1L with 
dissociation constants (Kd) of 33 nM and 206 nM respectively, agreeing well with 
a 1:1 interaction model (Figure 2.4A).  
These studies confirmed that DOT1L directly interacts with AF9 and ENL 
and for the first time the binding affinity of DOT1L to AF9 and ENL were 
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Table 2.1 Binding affinities of AF9 and ENL proteins to full length DOT1L and 
different constructs of DOT1L immobilized on a CM5 sensor chip 
Immobilized Proteins AF9  (497-568) 
Kd ± SD [nM] 
ENL (489-559) 
Kd ± SD [nM] 
DOT1L (1-1537)* 33 ± 4 206 ± 80 
DOT1L (826-1095) 111 ± 10 238 ± 72 
DOT1L (826-958) 92 ± 8 122 ± 16 
DOT1L (826-937) 78 ± 15 81 ± 6 
DOT1L (854-1095) 135 ± 4 148 ± 14 
DOT1L (925-1095) 1,825 ± 276 6,220 ± 113 
DOT1L (854-925) 42 ± 2 90 ± 12 
 
determined quantitatively.   
The C-terminal unstructured region of DOT1L has been reported to be 
involved in the interaction with AF9 and ENL [10, 23] (Figure 2.2). Consequently, 
we cloned and expressed the 826-1095 fragment from DOT1L and studied the 
interaction of this recombinant protein with AF9/ENL. SPR analysis showed that 
this segment of the DOT1L protein has Kd values of 111 nM and 238 nM to AF9 
and ENL protein respectively (Figure 2.4B), similar to those of the full length 
DOT1L (Figure 2.4A), confirming that this region in the DOT1L protein is 
essential for interactions with AF9/ENL proteins.  
To further map the region of DOT1L required for the AF9/ENL interaction, 
a series of truncated constructs of DOT1L (826-1095), devised according to 
predicted stability, were  designed, cloned, expressed and tested for their binding 
to AF9 and ENL (Table 2.1) . 
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The SPR studies show that truncation of the DOT1L protein on the N-
terminal site up to residue 854 and C-terminal deletions of up to residue 937  
failed to affect the interactions with AF9 and ENL and the measured binding 
affinities were in a similar range. However, further deletion of the N-terminal 
region and testing of the truncated DOT1L construct (925 to 1095 residues) 
showed 30-fold and 50-fold decreases in binding affinity for ENL and AF9 
respectively, clearly demonstrating the importance of the sequence 854 to 925 
for the binding to MLL fusion proteins. Based on this and the fact that the DOT1L 
(854-1095) fragment binds with binding affinity similar to that of the full length 
DOT1L protein, the DOT1L construct (854-925) was cloned and tested. 
Consistent with predictions, this shortest DOT1L fragment showed similar binding 
affinity to AF9 and ENL to that of the full length DOT1L with Kd values of 42 nM 
and 90 nM, respectively (Table 2.1). These results confirm that DOT1L (854-925) 
contains a domain that interacts specifically with MLL-fusion proteins, AF9 and 
ENL.  
2.4.2 Identification of a conserved peptide motif in DOT1L essential for 
binding AF9/ENL 
It is known that the C-terminal hydrophobic AF9/ENL domains in MLL-
fusion proteins retain the ability to form independently higher order complexes 
with AF4/p-TEFb and with DOT1L, demonstrating that the associations of 
AF9/ENL with AF4 and DOT1L are mutually exclusive [14, 23]. The AF9-binding 
domain of AF4 is known and is conserved among the AF4 homologs [17]. Based 
on these findings we predicted that the AF9/ENL interacting site in DOT1L might 
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Figure 2.5 (A). Alignment of human DOT1L (865-880) with human AF4 (761-
774). The conserved residues are marked with an asterisk, and the similar amino 
acids with dots. B. Alignment of the identified AF9/ENL binding site in DOT1L 
protein from different species. 
share some similarity with the AF4 protein. A small 16-residue region in DOT1L 
(865-880) was identified by alignment of the shortest fragment of DOT1L (854-
925) involved in AF9/ENL interactions with the AF9-binding domain of AF4 (761-
774). This region shares sequence homology with AF4, and includes four 
conserved and four similar residues (Figure 2.5A).  
Significantly, alignment of DOT1L from different species demonstrated 
that this fragment is highly conserved (Figure 2.5B). Based on this result we 
synthesized two peptides, DOT1L10mer (865-874) and DOT1L16mer (865-880) 
and, using several binding assays such as SPR, fluorescence polarization (FP), 
and isothermal titration calorimetry (ITC) examined whether the conserved 
peptide motif is sufficient for interaction with AF9 and ENL. Applying a 
competitive SPR assay, we tested the ability of 16mer and 10mer synthetic 
peptides to inhibit the PPI between DOT1L and AF9 or ENL.  
The results obtained demonstrate that both 16mer and 10mer peptides 
can block the PPI between DOT1L/AF9 and DOT1L/ENL with similar IC50 values, 
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Figure 2.6 Binding studies of DOT1L peptides with AF9/ENL proteins. (A) SPR 
competitive binding curves of DOT1L 16mer, 10mer, 7mer and AF4 14mer peptides 
against AF9 (497-568) and ENL (489-559) proteins using different tested 
concentrations over CM5 chip with immobilized DOT1L (826-1095). (B) Binding 
affinities of fluorescent-labeled DOT1L 10-mer peptide against AF9, ENL and mutated 
ENL L550E. (C) Fluorescence polarization (FP) competitive binding curves of AF4 
(749-775) recombinant protein and AF4 14mer peptide using fluorescein-labeled 
DOT1L 10mer peptide. 
0.49 µM and 0.32 µM respectively, against AF9, and 1.34 µM and 1.56 µM 
respectively, against ENL (Figure 2.6A). We tested the fluorescent labeled 
DOT1L 10mer peptide and found that it binds to the MLL fusion proteins, AF9 
and ENL, with Kd values of 0.065 μM and 0.495 μM respectively (Figure. 2.6B).  
To further confirm these binding results, an ITC assay using MBP-tagged 
ENL protein (Figure 2.7) was employed. Consistent with the FP-based results, 
both peptides, DOT1L 16mer and 10mer, bind to the ENL protein with similar 
binding affinities and Kd values of 0.9 µM and 1.1 µM, respectively in 1:1 
stoichiometry (Figure 2.7A and B). DOT1L 16mer binds to MBP-AF9 with a Kd of 
0.38 µM in 1:1 stoichiometry (Figure 2.7D). The binding results obtained for 
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Figure 2.7 Isothermal titration calorimetry (ITC) of MBP-ENL (489-559) (80 μM) with 
a solution of DOT1L 16-mer (400 μM) (A) and 10-mer (400 μM) (B), and for DOT1L 
7-mer peptide (500 μM) (C) and MBP-AF9 (497-568) (30 µM) with DOT1L 16-mer 
peptide (300 µM) (D).110 μM MBP-ENL was used. For all titrations, the raw data 
are shown in the upper panel, and the integrated calorimetry data are shown in the 
lower panel.  
 
DOT1L 16mer and 10mer peptides are consistent with our direct binding studies 
of the PPI (Table 2.1) and  provide strong evidence that peptide motif identified in 
DOT1L is both necessary and sufficient for interaction with AF9 and ENL. 
Since the identified DOT1L peptide shows sequence homology with the 
reported AF4 peptide, and the associations of AF9 and ENL with AF4 and 
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DOT1L through their conserved C-terminal domain have been reported to be 
mutually exclusive [14, 23], competition experiments were carried out between 
DOT1L and AF4 for binding to MLL-fusion proteins. For this purpose we 
expressed and purified AF4 recombinant protein (749-775 residues) and 
synthesized the AF4 14mer peptide (761-774) [17]. As expected, we found that 
the recombinant AF4 protein and AF4 14mer peptide efficiently competed away 
the binding of DOT1L 10mer fluorescein-labeled peptide to the C-terminal 
domain of AF9 protein with similar IC50 values of 0.56 and 0.28 µM (Figure. 2.6C). 
The SPR solution competitive binding assay confirmed these results and showed 
that the AF4 14mer peptide is also able to inhibit the PPI between AF9-DOT1L 
and ENL-DOT1L, with potency similar to that of DOT1L 16mer and 10mer 
peptides, showing IC50 of 0.20 µM against AF9 and 0.43 µM against ENL (Figure. 
2.6A). These findings clearly demonstrate that DOT1L and AF4 bind with similar 
binding affinity and compete for the same AF9/ENL interaction site, the C-
terminal hydrophobic domain.  
2.4.3 Alanine-scanning mutagenesis studies of the interaction between 
DOT1L 10mer peptide and MLL-fusion proteins  
Alanine scanning mutagenesis involves systematic replacement of amino 
acid residues with alanine.  Alanine was the residue chosen to replace the amino 
acids under examination because it maintains the stereochemistry of the 
backbone, while eliminating all of the side chain atoms beyond the β-carbon. It 
can yield important functional insight about PPIs for which there is no structural 
information. We performed systematic alanine mutagenesis to identify positions 
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Figure 2.8 Binding affinities of alanine mutated DOT1L 10-mer peptides to AF9 (A) 
and ENL (B) compared with the wild type DOT1L 10-mer peptide.  
in DOT1L that make essential contacts with the MLL-fusion proteins, AF9 and 
ENL. We mutated to alanine each of the DOT1L residues from Leu865 to Val874, 
thus creating 10 different DOT1L mutants and, in an SPR-based competitive 
assay determined their potency as inhibitors of the PPI.  
Using wild type DOT1L10mer peptide as a standard, we compared the 
binding affinities of each of these ten alanine-mutated DOT1L - based peptides, 
obtaining the results shown in Figures 2.8.  
The three conserved residues in DOT1L, L865, I869 and L871, as well as 
the similar residue, I867, all failed to tolerate alanine substitution, showing 
significant decrease in binding affinity to both AF9 and ENL proteins. These 
results demonstrate the importance of the hydrophobic interactions which is 
consistent with notion of a conserved C-terminal hydrophobic domain in both AF9 
and ENL. The non-conserved residues, P866, S868 and P870 showed 10- to 40-
fold reductions in their ability to inhibit the PPI. Interestingly, mutation of the last 
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three residues, S872, T873 and V874 in the DOT1L-10mer peptide, was 
tolerated well showing only 2- to 6-fold decrease in the binding affinity compared 
to the wild type peptide. We synthesized wild type 7mer DOT1L peptide (865-871) 
and tested its binding to AF9 and ENL. Consistent with the mutation data this 
peptide showed an 8-fold reduction in the binding to AF9 and a 5-fold reduction 
in binding affinity to ENL protein when compared with the 10mer peptide (Figure 
2.8A and B). The binding affinity of DOT1L 7mer peptide to ENL protein was 
confirmed in an ITC assay showing a Kd of 3.4 µM, 3-fold lower in comparison 
with the 16mer and 10mer DOT1L peptides (Figure 2.7C). Therefore the alanine 
scanning mutagenesis studies indicate that the heptapeptide binding motif of 
DOT1L is essential for interactions with MLL-fusion proteins and in fact is the 
minimum required fragment. In addition, the results obtained show a similar 
pattern in the binding of all tested peptides against AF9 and ENL proteins, 
suggesting that they share similar structural requirements for this interaction; a 
single amino acid mutation of the hydrophobic conserved residues is sufficient to 
disrupt the PPI. Overall, these findings provide a rationale towards future efforts 
in identifying chemical probes that can disrupt the interaction between DOT1L 
and the MLL-fusion proteins.  
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Figure 2.9 (A) Alignment of AF9/ENL C-terminus domains, AF9 (497-568 and ENL 
(489-559). Conserved residues are highlighted with asterisk. (B) Binding 
sensorgrams of immobilized Mocr-DOT1L (826 - 1095) with ENL H1 (489-544) and 
ENL H2 (523-559), tested in the concentration ranges 1 - 16 µM and 5 - 35 µM, 
respectively. The kon, koff and Kd were calculated by simultaneous non-linear  
regressions using a 1:1 binding model and BIAevaluation 3.1 software. The 
experimental data are shown in black while the global fit analyses are shown in red.  
 
2.4.4  The entire C-terminal domain of ENL is required for interaction with 
DOT1L 
Secondary structure predictions of the C-terminal hydrophobic domain in 
AF9 and ENL indicate the presence of two highly conserved helical segments 
(Figure 2.9A). Deletion of either of these helical regions completely abrogates the 
transforming activity of MLL-AF9 and MLL-ENL fusion proteins [32]. To 
determine if the helical regions are important for the binding of these two MLL-
fusion proteins to DOT1L, we prepared ENL H1 (489-544) and ENL H2 (523-559), 
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two recombinant fragments of ENL protein which correspond to predicted helices 
1 and 2, respectively [32]. It was determined that ENL H1 binds to DOT1L (826-
1095) with KD of 2.8 μM and ENL H2 binds with Kd of 14.6 μM (Figure 2.9B), 
demonstrating 10-fold and 30-fold decreased binding affinity respectively in 
comparison with the intact ENL C-terminal domain (Table 2.1).  
These results demonstrate that the entire C-terminal domain from ENL is 
required for optimal interaction with DOT1L, which is consistent with the reports 
that both helical segments are essential for the transformation potential of MLL-
ENL fusion protein [5]. To further map and identify the so called “hot-spot” 
residues in C-terminal domain of ENL, those that are essential for the interaction 
with DOT1L, we prepared ENL mutant, L550E, which has been reported to block 
the transforming capacity of the MLL-ENL fusion protein [23]. As was predicted, 
the fluorescein-labeled DOT1L 10mer peptide failed to bind to this mutant protein 
(Figure 2.6B). The result obtained identified this conserved residue, L550 and 
L558 in ENL and AF9, respectively, as a hot-spot and demonstrated that is 
essential for the interaction with DOT1L.  
2.4.5 Binding of DOT1L to the C-terminus domain of ENL induces folding 
of ENL  
NMR spectroscopy was used to gain more information and understanding 
of the DOT1L-ENL PPI at the structural level, and to determine conclusively 
whether DOT1L peptides specifically interact with ENL. We obtained high-quality 
HSQC (Heteronuclear Single Quantum Correlation) spectra of 15N-labeled ENL 
(489-559) protein. The 1H-15N HSQC spectra of 15N-labeled ENL (489-559) 
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protein alone (Figure 2.10A) showed poor signal dispersion, indicating that the 
protein is intrinsically disordered.   Addition of the DOT1L protein (826-1095) 
however (Figure. 2.10A, red spectrum) in a 1:1 ratio, resulted in folding and 
binding, and the spectrum of the ENL-DOT1L complex shows very extensive 
chemical shift dispersion consistent with a well folded and stable structure. 
Comparison of the HSQC NMR spectra of DOT1L-ENL complexes with DOT1L 
16mer (red spectrum), 10mer peptide (blue spectrum) and 7mer peptide (green 
spectrum) (Figure 2.10B), showed very similar chemical shifts and overall, the 
HSQC spectrum of the ENL-DOT1L peptide complexes overlap with the 
spectrum of the complex with DOT1L protein. These results further confirm that 
all three peptides are able to completely recapitulate the chemical shifts of 
DOT1L protein, and that they bind in a similar way.  Consistent with our binding 
results, the NMR data further demonstrate that all tested DOT1L peptides 
interact directly with ENL and the heptapeptide binding motif of DOT1L is 
essential for these interactions and represents the minimum required motif.   
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Figure 2.10 Binding of DOT1L to ENL C-terminal domain induces folding of ENL. 
(A) Overlay of 1H-15N HSQC spectrum from 15N ENL (489-559) (80 μM, black) and 15N 
ENL (489-559) in complex with DOT1L (826 - 1095) protein in 1:1 molar ratio (red) (B) 
Overlay of 1H-15N HSQC spectrum from  15N ENL (489-559) (80 μM, black) and 15N 
ENL (489-559) in a complex with DOT1L 16-mer peptide  (red),  DOT1L 10mer 
peptide (blue) or DOT1L 7mer peptide (green) in 1:1 molar ratio.  
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2.4.6 Homology modeling of DOT1L-ENL complex 
Recently the structure of AF9-AF4 complex was determined using NMR 
spectroscopy (PDB ID: 2LM0) [33]. Consistent with our findings this study also 
demonstrate that the AF9 C-terminal hydrophobic domain is intrinsically 
disordered and folds upon binding to AF4. To take advantage of this structural 
information and to better understand the structural basis of ENL-DOT1L PPI, we 
have generated a homology model of ENL in complex with DOT1L 7mer peptide. 
The C-terminal domain of AF9 shows the highest homology to the C-terminus of 
ENL (amino acids 473 - 568) and therefore the reported NMR structure was used 
as a template. MOE-align results showed that MLL fusion proteins, ENL and AF9, 
have high identity and similarity and based on the sequences aligned, the identity 
of ENL to AF9 is 79.2%. The accuracy of the structures generated by homology 
modeling is highly dependent on the sequence identity between the target and 
the template protein. Since ENL and AF9 shared high level od identity the 
generated homology model is accurate and reliable and can be used for structure 
based studies . 
The generated homology model showed that the interface between ENL 
and DOT1L 7mer peptide is extensive and hydrophobic, with four aliphatic 
residues from DOT1L making hydrophobic interaction, especially I867 and I869 
which are buried deeply into the hydrophobic core of ENL (Figure 2.11). This 
model is strongly supported by our alanine mutagenesis studies which 
demonstrated that mutating these hydrophobic residues to alanine abolished the 
binding of DOT1L peptide to ENL protein (Figure 2.8). Ser 868 of the DOT1L 
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Figure 2.11 Homology model of ENL in complex with DOT1L 7mer peptide. (A) 
The DOT1L 7mer peptide, LPISIPL, is in a long and deep hydrophobic channel. 
(B) Three hydrogen bonds were revealed for the ENL – DOT1L complex.  
peptide is not involved in the hydrophobic interactions and it is in close proximity 
to the Asp 536 of ENL. Therefore, mutating of Ser 868 to a Ala may induce 
decrease of the binding affinity which was confirmed with alanine scanning 
mutagenesis studies. The minimized ENL-DOT1L homology structure indicated 
that there are at least three hydrogen bonds: two between Phe 537 of ENL and 
Ile 867 of DOT1L peptide and one between Phe 535 of ENL and Ile 869 of 
DOT1L.  
In addition, our binding studies demonstrated that L550E point mutation  in 
ENL protein is disrupting the binding of DOT1L peptide (Figure. 2.6B). According 
to the homology model of ENL complex with DOT1L peptide, L550 is buried in 
the protein interior through hydrophobic interactions and is involved in packing 
together secondary structure elements. Mutation of L550 to glutamic acid will 
have impact on the conformation of the binding pocket and probably on the 
overall folding of the protein, resulting in no binding of the DOT1L peptide to the 
protein. 
Therefore, this model will allow further understanding of this PPI on the 
molecular level as well as gaining knowuledge about other PPI that AF9 and ENL 
are involved. Furthermore, knowing the interactions between DOT1L peptide and 
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Figure 2.12 DOT1L 10-mer peptide binds cellular MLL-AF9 fusion protein and 
disrupts its interaction with DOT1L. (A) DOT1L 10-mer peptide disrupts the 
interaction between DOT1L and MLL-AF9 in cells. Flag-DOT1L and Myc-CxxC-AF9 
were co-transfected in HEK 293 cells and co-IP was performed. (B) Pull-down assay 
using biotin-labeled DOT1L 10-mer peptide. (C) FP competitive curve of BL-DOT1L 
and DOT1L 10mer peptide in the pull-down assay. 
ENL on the structural level will provide critical insights towards developing 
peptidomimetics as one of the known strategies for targeting PPI. 
2.4.7 DOT1L 10mer peptide disrupts in vivo interactions of full length 
DOT1L with MLL-AF9 fusion protein 
 
To assess whether the DOT1L 10mer peptide can bind and block the 
interaction between full length DOT1L and MLL-fusion proteins, we transiently 
co-transfected HEK 293 cells with Flag-tagged human DOT1L protein and Myc-
tagged CxxC-AF9 protein. The whole cell lysate was pre-incubated with different 
concentrations of DOT1L 10mer peptide and co-immunoprecipitation (co-IP) 
experiments were performed (Figure 2.12A).  
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The results obtained demonstrate that the DOT1L 10mer peptide blocks 
the interaction of cellular DOT1L with CxxC-AF9 in a dose-dependent manner 
(Figure 2.12A). To further probe and confirm the cellular target for DOT1L 10mer 
peptide, we synthesized a biotinylated DOT1L 10mer peptide and to determine 
the binding affinity of this labeled peptide we used FP competitive based assay, 
which was tested together with the corresponding unlabeled DOT1L 10mer 
peptide.  
The IC50 values obtained were similar, confirming that biotin labeling did 
not affect its binding to AF9 protein (Figure 2.12C). Using this peptide as a tool, 
we performed streptavidin-biotin pull-down experiments in the HEK 293 cell 
lysates that showed that the biotinylated DOT1L 10mer peptide recognizes and 
binds to the cellular CxxC-AF9 protein in a dose- dependent manner (Figure 
2.12B). Together, these experiments demonstrate that the DOT1L 10mer peptide 
binds to the cellular AF9 protein and blocks its interaction with DOT1L, consistent 
with our in vitro binding data using recombinant MLL-fusion proteins.  
2.4.8 Identified 10 residues are essential for DOT1L recruitment and MLL-
AF9 leukemic transformation 
To assess further the functional importance of the recruitment of DOT1L 
by MLL-fusion proteins and determine whether the 10 residue segment identified 
in DOT1L is required for MLL-AF9 transformation, we performed colony forming 
unit (CFU) assays (Figure 2.13).  
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Figure 2.13 AF9 binding site in DOT1L is essential for MLL-AF9 leukemic 
transformation. (A) Schematic presentation of the colony formation unit (CFU) 
assay. (B) Genotyping of transduced bone marrow cells. The PCR reaction showed 
high excision efficiency of endogenous DOT with 4-OHT treatment of all cells. (C) 
Quantitative PCR of exogenous DOT1L expression. All constructs showed 
expression compared with Neo vector alone. (D) Western blot of H3K79me2 global 
level. Histone 3 blot was used as loading control. (E) and (F) Colony formation on 
methocult plates. Pictures of iodonitrotetrazolium chloride staining (E) and bar graph 
of colony counts (F) after the second round.  
 In these experiments MSCV-based vectors were used to transduce mouse 
bone marrow cells with leukemogenic MLL-AF9 fusion protein from floxed Dot1l 
mice generated as described previously [25]. HA-tagged wild-type mouse DOT1L, 
methytransferase inactive full-length mDOT1L (RCR) with GSG to RCR mutation 
in the S-adenosylmethionine binding domain and lack enzymatic activity [19, 34], 
full-length mDOT1L 10aa∆ lacking ten amino acid AF9 interacting residues (863 
to 872 which are conserved and correspond to the human DOT1L 865 to 874, 
Figure 2.5B), or neomycin vector control were introduced into endogenous 
DOT1L lacking MLL-AF9 transformed cells (Figure 2.13A). Endogenous Dot1l 
excision was confirmed by PCR and expression of exogenous DOT1L by 
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quantitative PCR of HA tag sequences (Figure 2.13B and C). As was expected, 
wild-type DOT1L was able to restore H3K79 methylation while mDOT1L (RCR) 
failed to restore H3K79 methylation (Figure 2.13D). Interestingly, mDOT1L 
10aa∆ with an intact histone methyltransferase domain was also able to restore 
the H3K79 methylation although slightly decreased in comparison with wild-type 
DOT1L. It is also important to be pointed out that the global level of H3K79 
methylation was determined after the first round of replating. It was not possible 
to check for the global H3K79 methylation after the second round because there 
were not enough cells for the assay. Consistent with the reported findings, the 
colony forming potential of MLL-AF9-immortalized cells was completely 
abolished by introduction of an mDOT1L (RCR) construct after Dot1l deletion, 
while introduction of exogenous wild-type DOT1L was able to rescue the 
transformation capability and restore CFU formation (Figure 2.13E and F). 
Despite being able to restore H3K79 methylation level in a similar way as the 
wild-type DOT1L construct, the mDOT1L 10aa∆ construct failed to restore CFU 
formation (Figure 2.13E and F). These results strongly suggest that DOT1L 
interaction with MLL-AF9 and its recruitment are required for transformation by 
MLL-AF9, and full-length DOT1L lacking the AF9 interacting residues could not 
rescue CFU formation.  
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Figure 2.14 Binding of different DOT1L phosphorylated peptides to AF9 protein. 
(A) Competitive FP binding DOT1L phosphorylated peptides to AF9 protein. (B). 
Calculated change of fold in IC50 of DOT1L phosphorylated peptides compare  to 
DOT1L 10mer. 
2.4.9 Post-transcriptional modification as a potential mechanism for 
regulation of the AF9/ENL-DOT1L protein-protein interaction 
2.4.9.1 Phosphorylation of serine 868 in DOT1L abolishes the AF9/ENL-DOT1L 
protein-protein interaction  
The effects of phosphorylation regulating protein-protein interactions have 
been reported earlier [35, 36]. Since serine (S868 and S872) and threonine 
(T873) are present in the DOT1L peptide, we speculate that phosphorylation 
might be involved in regulation of the AF9-DOT1L interaction. To investigate the 
possible role of phosphorylation in regulation of the AF9-DOT1L interaction, we 
synthesized the corresponding DOT1L peptides, with S868, S872 or T873 
phosphorylated.  
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Figure 2.15 Mass spectrometry-based analysis of DOT1L phosphorylation. 
(A) Schematic of experimental design. (B) Representative Coomassie blue stained 
gel of Flag-DOT1L protein expressed in 293 cells. 
The binding of these peptides to AF9 proteins was tested by FP-based 
competitive assay (Figure 2.14A). Phosphorylation of S872 or T873, had no or 
minimal effect on the AF9-DOT1L interaction, whereas phosphorylation of S868 
largely abolished the interaction. DOT1L pS868 10mer peptide showed about a 
100-fold increase in the IC50 against AF9-DOT1L interaction (Figure 2.14B) 
compared to the DOT1L 10mer, indicating that phosphorylation of S868 in 
DOT1L might be involved in regulation of the AF9-DOT1L interaction.  
2.4.9.2 Mass spectrometry approach to the identification of phosphorylation sites 
in DOT1L 
There are no reports about the phosphorylation at S868 in DOT1L. To 
study further the effects of phosphorylation on DOT1L, we prepared the full 
length Flag tag human DOT1L protein overexpressed in 293 cells and immune-
precipitated by anti-Flag antibody (Figure 2.15A).  
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Figure 2.16 A representative MS/MS spectrum of the DOT1L tryptic peptides which 
contain the AF9 interaction region. DOT1L was immunoprecipitated and subjected to 
LC-MS/MS analysis. A representative MS/MS spectra assigned to 
854AYGSSGELITSLPISIPLSTVQPNK878 (precursor ion [MH]+3= 858.16 m/z) are shown.  
Observed b- and y-ions are indicated. 
 
The protein sample was stained with Coomassie blue. The major protein 
band in the sample, with a molecular weight of about 180 kDa, corresponding to 
DOT1L protein, was cut out and used for trypsin digestion and mass 
spectrometry analysis (Figure 2.15B).  
The peptide corresponding to DOT1L 854-878, was identified (Figure 
2.16). No phosphorylation was observed however in S868, which is potentially 
involved in regulation of the AF9-DOT1L interaction.  
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Figure 2.17 Scheme of Formation of covalent adducts from Bap and 
proteins 
2.4.10 Photo-affinity crosslinking approaches to study of the AF9/ENL-
DOT1L interaction 
2.4.10.1 Design of DOT1L photo-affinity peptides 
Covalent cross-linking has been used successfully to study protein-protein 
interactions and identification of drug targets [37, 38] [39-41]. Benzophenone is 
one of the most popular photophores used in photo-affinity labeling. A non-
natural amino acid bearing a benzophenone moiety (3-benzoylphenylalanine, 
Bpa), which covalently crosslinks to protein targets upon exposure to ultraviolet 
(UV) light, was chosen for covalent crosslinking. Bpa has clean photochemistry 
and high stability in the conditions of peptide synthesis [39]. Benzophenone 
derivatives react via a triplet biradical mechanism [41](Figure 2.17) with a high 
preference for reaction with C-H bonds in proximity of 2.5–3.1Å [40]. Thus, the 
Bpa residue is particularly useful for labeling proteins. To better understand the 
DOT1L-AF9 interaction, we applied Bpa photo-affinity crosslinking approaches to 
its study. 
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Figure 2.18 Design of DOT1L-Bpa peptide for crosslinking. (A) Sequences of different 
DOT1L-Bpa peptides. (B) Fluorescence polarization (FP) competitive binding affinities of 
DOT11L-Bpa to peptides to DOT1L-AF9 interaction. 
DOT1L-Bpa peptides are designed to incorporate Bpa into the peptide. 
Typically, Bpa was introduced to substitute conservative aromatic residues in the 
peptide [39, 42, 43] but, since there are no aromatic amino acids in our DOT1L 
peptide, we chose to introduce Bpa between S872 and T873, a position in close 
proximity to the core hydrophobic interaction residues (865-871), but not affecting 
the binding of the peptide to AF9/ENL protein. We designed several DOT1L 
related peptides, including BL-DOT1L-Bpa, with N-terminal biotin. As a control, 
phenylalanine was introduced at the same position as Bpa; a tryptic site at the 
non-interacting site of DOT1L peptide was introduced in order to ensure that the 
Bpa crosslinking protein was optimal for sequencing by mass spec analysis 
(Figure 2.18A). Fluorescence polarization based competitive assays performed 
using Flu-DOT1L peptide and recombinant GB1-AF9 protein confirmed that Bpa 
incorporation did not affect the target binding (Figure 2.18B). 
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Figure 2.19 (A) Crosslinking product of BL-DOT1L-Bpa 
peptides with GB1-AF9 proteins by Commassie blue 
staining. (B) Western blot of BL-DOT1L-Bpa peptides and 
GB1-AF9 crosslinking product. (C) Crosslinking product of 
DOT1L-K-Bpa-COOH peptide with GB1-AF9 protein by 
Commassie blue staining. (D) Crosslinking of DOT1L-Bpa 
peptides with GB1 tag. 
2.4.10.2 DOT1L-Bpa peptides crosslinking with recombinant GB1-AF9 
protein 
The designed peptides, including Biotin-DOT1L-Bpa and DOT1L-K-Bpa, 
were incubated with GB1-AF9 at a ratio of 1:1. Upon exposure to UV light, these 
two peptides are able to bind to GB1-AF9 and form the crosslinking product, 
which was detected by Coomassie staining (Figure 2.19A and C).  
Western blot using antibodies against biotin indicate the specificity of the 
formed product. To 
exclude the possibility 
that GB1 tag might be 
involved in the 
crosslinking, DOT1L-
Bpa peptide was 
incubated with GB1 tag 
alone. No crosslinking 
products were observed 
upon UV exposure, 
indicating that the covalent capture of GB1-AF9 protein by DOT1L-Bpa is indeed 
selective (Figure 2.19D).  
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Figure 2.20 Crosslinking and pull down of AF9 
protein in 293 cell lysates. (A) Scheme of 
crosslinking and pull down assay of AF9 proteins by 
BL-DOT1L-Bpa peptides. (B) Western blot of 
crosslinked CxxC-AF9 protein. 
2.4.10.3 DOT1L-Bpa peptide crosslink with overexpressed cellular AF9 
protein 
Having demonstrated DOT1L-Bpa peptide was selective for its protein 
target in vitro, we next investigated whether the photo-reactive peptide could 
target and crosslink to its 
physiologic binding 
partners. We incubated 
biotinylated DOT1L-Bpa 
peptide with a cellular 
extract from 293 cells 
overexpressed with Myc-
CxxC-AF9 protein in the 
presence of UV irradiation, 
followed by SA-based pull-
down, stringent washing to eliminate non-covalent binders, and western blot 
analysis. While UV irradiated cell extracts treated with the DOT1L-Phe control 
peptide showed no cross-linked product, DOT1L-Bpa peptide crosslinks to 
endogenous Myc-CxxC-AF9 proteins in a dose-dependent manner (Figure 2.20A 
and B). 
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2.5 Discussion 
2.5.1 AF9 or ENL-DOT1L interaction is a promising therapeutic target  
We have identified and mapped the protein-protein interaction site 
between DOT1L and MLL-fusion proteins, AF9 and ENL. Using SPR and FP 
based binding assays, ITC, HSQC NMR, immunoprecipitation and pull-down 
experiments, we determined the binding affinity of these PPIs and defined the 
AF9/ENL interaction site as the region corresponding to DOT1L 
865LPISIPLSTV874. The importance of this binding region is indicated by its 
conservation in different species. Our in vitro and in vivo findings demonstrated 
that the corresponding synthetic DOT1L 10mer peptide can competitively 
interfere with the interaction between MLL-fusion proteins, AF9 and ENL, and 
DOT1L. The alanine scanning mutagenesis studies showed the critical 
importance of several conserved residues, L865, I867, I869 and L871, for binding 
to AF9 and ENL. Binding studies confirmed a direct interaction between AF9/ENL 
and DOT1L, and showed that an intact C-terminal domain in MLL-fusion proteins 
is critical for optimal interaction. Furthermore, ENL mutant, L550E, which was 
reported to block the transforming capacity of MLL-ENL fusion protein [23], 
completely lost its ability to interact with DOT1L 10mer peptide. These results 
together with reported functional studies further demonstrate a high correlation 
between the DOT1L recruitment and the transforming potential of MLL-ENL. 
Several groups have demonstrated that DOT1L is required for MLL-AF4 and 
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MLL-AF9 fusions-mediated leukemic transformation [25, 44-47], establishing the 
crucial role of DOT1L in MLL-rearranged leukemia [48] and, consistent with these 
findings, our functional studies using a colony forming unit assay provide strong 
evidence that the identified DOT1L865-874 fragment is essential for the DOT1L 
recruitment and MLL-AF9 leukemic transformation. The colony forming potential 
of the MLL-AF9 immortalized cells was completely abolished by introduction of a 
DOT1L construct lacking the 10 amino acid AF9 interacting residues. In addition 
to H3K79 methylation, these results highlight the importance of the DOT1L 
recruitment and its interaction with MLL-AF9 for the transforming activity of this 
MLL fusion oncogene.  
We thus validated the PPIs between DOT1L and AF9 or ENL, respectively, 
as promising therapeutic targets and the basis of a potential strategy for 
pharmacological targeting of DOT1L. Our results indicate that disruption of AF9-
DOT1L interaction abolishes MLL-AF9 leukemia transformation, without affecting 
the global level of H3K79 methylation level. More importantly, they also suggest 
that selective disruption of this PPI is a promising therapeutic strategy with 
potentially fewer adverse effects than enzymatic inhibition of DOT1L for MLL-
fusion protein associated leukemia.  
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Our binding studies clearly demonstrate that DOT1L and AF4 proteins, as 
well as the DOT1L 10mer and AF4 14mer peptide, bind to the same C-terminal 
hydrophobic domain of AF9 and ENL (Figure 2.20A), consistent with biochemical 
and functional analyses of protein complexes associated with MLL-fusion 
proteins. This shows that AF9 and ENL exist in two mutually exclusive 
complexes, AF9/ENL-DOT1L and AF9/ENL-AF4-pTEFb [14, 23].  
Based on our results, we propose that small molecules that bind to the 
conserved hydrophobic domain of AF9 and ENL should abolish the AF9 
interactions with both AF4 and DOT1L, disrupt the higher order complex AEP 
and the complex with DOT1L, and thereby blocking the MLL fusion-mediated 
leukemogenesis (Figure 2.20B). Taken together, this study supports the 
 
Figure 2.21 Schematic of proposed model for targeting DOT1L and MLL-fusion 
protein-protein interactions. A. AF9 binding sites mapped in DOT1L and AF4 
proteins (Srinivasan et al, 2004). B. A small-molecule inhibitor (SMI) that binds to C-
terminal domain of AF9/ENL will disrupt the MLL-fusion protein complexes involved in 
mixed lineage leukemia, the DOT1L and AEP complex. 
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hypothesis that DOT1L recruitment is a potential therapeutic target in MLL-
rearranged leukemia and discovery and development of chemical probes that 
can block these PPI is warranted. 
2.5.2 Signal transduction as potential mechanism for regulation of DOT1L 
recruitment 
As an important post-transcription modification, phosphorylation is widely 
involved in the regulation of protein-protein interactions by affecting the stability, 
kinetics and specificity of interactions [49]. Our results show that phosphorylation 
of S868 of DOT1L abolishes the AF9-DOT1L interaction, indicating that 
phosphorylation might be involved in regulation of DOT1L recruitment by AF9 
and ENL. Recently it has been reported that phosphorylation of T766 of AF4 also 
resulted in a ~30-fold reduction in the affinity for interaction with AF9 [33]. 
Together with our findings, these results indicate that phosphorylation sites within 
the consensus AF9 binding sequences may allow transient and reversible 
regulation of the interaction. Although phosphorylation of S868 was not identified 
in our mass spectrometry analysis, several considerations should be taken into 
account before reaching a definite conclusion. The exogenous tagged DOT1L 
protein overexpressed in 293 cells may not be an optimized system for studying 
DOT1L phosphorylation since some phosphorylation events are specific to cell 
type and cell cycle [50], and several  approaches can be applied to further 
explore the role of phosphorylation in regulating DOT1L recruitment. Production 
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of phosphorylated S868 specific antibodies and profiling the panel of cell lines 
with the specific antibody might give some insights into the phosphorylation 
status.  Predictions according to Human Protein Resource data base and based 
on the sequence of the DOT1L 10mer peptide indicated that this region might be 
a possible substrate motif of several Ser/Thr kinases, including GSK-3, MAPPK, 
PTK. Another approach might be use of the DOT1L peptides as substrates and 
screening a panel of Ser/Thr kinases, to determine if the Ser868 might be the 
substrate of certain known kinases.   
2.5.3 DOT1L photo affinity peptide may serve as a useful research tool for 
MLL 
Many critical biological interactions are transient or are of insufficient 
affinity to withstand the experimental conditions required to prepare cellular 
extracts or isolate complexes by affinity chromatography. Our results indicate 
that DOT1L-Bpa peptide was able to trap the transitory interactions as well as 
static binding events and can be applied to probe the mechanisms of dynamic 
MLL fusion protein complexes (Figure 2.20). In addition, photo-crosslinking 
approaches have been applied to locate protein interaction sites in combination 
with MS/MS and computational docking strategy. We have also developed 
DOT1L-Bpa peptides optimal for mass spectrometry analysis (Figure 2.18A). The 
DOT1L-K-Bpa peptide showed similar binding affinities as the DOT1L 10mer 
peptide (Figure 2.18B), and was able to crosslink with GB1-AF9 efficiently 
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(Figure 2.19C). A unique and compelling feature of this approach is the ability to 
conduct rigorous validation studies for the identified targets and their sites of 
interaction. DOT1L-Bpa peptides might serve as research tools that efficiently, 
selectively, and irreversibly crosslink both static and dynamic protein targets for 
proteomic and mechanistic analyses in MLL. Thus, the development and 
application of photo-reactive peptides represents a potentially powerful approach 
to identifying, distinguishing, and modulating protein targets relevant to 
pathologic cellular processes. 
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Chapter 3  
 Identification of small molecular inhibitor against AF9/ENL-DOT1L 
Protein-Protein Interaction by High-throughput Screening 
3.1 Abstract 
The MLL fusion proteins AF9 and ENL, activate target genes in part via 
recruitment of the histone methyltransferase DOT1L (Disruptor Of Telomeric 
silencing 1-Like). In this Section, we report characterization of the protein-protein 
interaction between DOT1L and AF9/ENL. Binding studies demonstrate that only 
10 amino acids in DOT1L are involved in the interaction with AF9/ENL and four 
of these are conserved hydrophobic residues essential for this PPI. Significantly, 
a DOT1L construct lacking the residues that interact with AF9/ENL completely 
abolishes the colony forming potential of the MLL-AF9 immortalized cells. This 
result demonstrates that the PPI of DOT1L and AF9/ENL is required for 
transformation of MLL-AF9 and suggests that disruption of this PPI is a promising 
therapeutic strategy for MLL-fusion protein-associated leukemia. We employed a 
high-throughput screening approach for the discovery of inhibitors targeting the 
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recruitment of DOT1L by MLL-fusion proteins. For this purpose we developed 
and optimized a fluorescence polarization (FP) based assay in a 384-well format 
using AF9 protein and fluorescein-labeled DOT1L 10mer peptide with a Z‟ factor 
of 0.75. Approximately 100,000 compounds were screened at a concentration of 
20 µM for their ability to inhibit binding of the DOT1L peptide to AF9. A total of 
1191 compounds with inhibitory activity larger than three standard deviations in 
primary screening were selected for a confirmatory assay in order to identify 
fluorescent compounds, quenchers and to confirm their binding.  A total of 164 
compounds were selected and tested in a dose-response screen and 39 active, 
structurally diverse compounds were identified. Eight of these compounds, 
whose selection was based on their potency, chemical structure and availability, 
were purchased and retested in the FP competitive assay. The activity of four 
compounds was confirmed in both assays with IC50 values from 10 - 60 µM in the 
FP assay, and 20 – 70 µM in the SPR assay. These compounds served as a 
starting point for the development of small molecule inhibitors of the AF9-DOT1L 
interaction. 
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3.2 Background 
3.2.1 Challenges of targeting protein-protein interactions 
Targeting the interactions between proteins has significant therapeutic 
potential [1-3], but discovery of compounds that can interfere with PPIs is not a 
trivial task. Protein-protein interfaces are likely to be wider and shallower than 
canonical small molecule binding sites on proteins [4, 5] and the contact surfaces 
involved in a typical PPI are from 1,500–3,000Ǻ2 [6, 7] compared with ~300–
1,000Ǻ2 surfaces involved in protein-small-molecule interaction[8, 9].  X-ray 
structures of protein-protein complexes show that protein-protein interfaces are 
generally flat and often lack the grooves and pockets that characterize the 
surfaces of proteins that bind to small molecules [10, 11]. Secondly, unlike 
classical protein targets such as enzymes and G-protein-coupled receptors, 
which have natural substrate or ligand as a starting point for inhibitor design, 
protein-protein interactions do not have natural small-molecule partners that can 
bind to the PPI interface.  
Several lines of evidence however provide encouragement to the search 
for small molecules that target protein-protein interfaces. Although these 
interfaces are large, mutational studies have shown that only a few of the 
residues involved in the protein-protein binding contribute to most of the free 
energy of binding [12-15]. These residues, known as “hotspots”, account for a 
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much reduced contact surface of the protein involved in the protein-protein 
interaction and are usually found at the center of the contact interface. The fact 
that all protein-protein interfaces that have been studied in detail contain hot 
spots of binding energy has important implications for the development of small 
molecules that disrupt PPIs. Hot spots, which generally account for less than 10 % 
of the whole protein-protein interface [15] effectively allow reduction of the target 
area in rational design studies from thousands of square Ǻngströms to a handful 
of key contacts in a specific area [12, 16-18] and targeting the “hot spots” may be 
a feasible strategy [5, 19]. 
3.2.2 Strategies of targeting protein-protein interactions 
Considerable progress has been made in the past decades in finding 
inhibitors that disrupt protein-protein interfaces and successful examples of the 
use of hot spots to drive rational design studies are beginning to appear in the 
literature [20]. There are several dominant strategies for the discovery of 
inhibitors that bind at protein-protein interfaces: use of protein peptide mimetics, 
screening of large chemical libraries via high-throughput screening, fragment 
based screening, and in silico screening. These approaches all have distinct 
benefits and drawbacks. 
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Peptidomimetics 
Peptidomimetics are compounds whose essential elements or 
pharmacophore, mimic a natural peptide or protein in 3D space and which retain 
the ability to interact with the biological target and produce the biological effects 
[21]. Peptidomimetics have been applied to the development of PPI inhibitors. A 
small-molecule peptidomimetic inhibitor of the MLL1/WDR5 protein-protein 
interaction was developed based on the minimum binding motif derived from 
MLL1 [22]. The designed peptidomimetic binds to the target protein WDR5, with 
high affinity (Ki <1 nM) and is a potent antagonist of MLL1 activity. 
High-throughput screening  
High-throughput screening (HTS) refers to the process by which large 
numbers of compounds, generally on the order of tens of thousands, are 
examined for their ability to bind to a target of interest. HTS has played an 
integral role in the identification of small molecule leads in drug discovery and 
since its first use in the early 1990s, it has become a well-established process in 
drug discovery research [23]. The development of automation technology and 
commercially available chemical libraries has allowed laboratories not 
specializing in chemistry to actively attempt to discover small molecules that 
modulate a macromolecular target of interest and a number of inhibitors of PPI 
have been identified by HTS. An early example is the screening of inhibitors 
  
89 
 
 
modulating the Bax/Bcl-xL interaction [24]. In this work, the authors used an initial 
in vitro fluorescence displacement screen with the fluorescently labeled BH3 
domain of Bak and Bcl-xL. From an initial screen of about 16,000 compounds, 
several hits with Kd in the low micromolar range for Bcl-xL were identified. These 
lead compounds were further tested in cells and were found to successfully 
induce apoptosis by interfering with the Bak/Bcl-xL interaction. Another example 
is the identification from an HTS of nutlins as p53-MDM2 interaction inhibitors. 
Co-crystallization of nutlins with the target protein MDM2 showed the nutlin 
effectively binding to and blocking the pocket that would have been occupied by 
the transactivation domain of p53. Further experiments revealed that these 
compounds bind to MDM2 and activate the p53 pathway in cancer cells leading 
to cell cycle arrest, apoptosis and inhibition of tumor growth in mice[25].  
Fragment based discovery 
The fragment-based discovery technique screens small components for 
binding to a protein of interest and subsequently links suitable motifs together. 
Generally, fragments are small organic compounds, typically less than 200 Da in 
mass, weak in binding affinity but with better ligand efficiency, which is a 
measurement of the binding energy per atom of a ligand to its binding partner.. 
Initially, fragment libraries are screened for binding to a protein target judged by 
biophysical or biochemical data. The fragments identified in this way can be 
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linked together through links spanning distant sites on the protein-protein 
interaction surface. The discovery of ABT-737, which is a Bcl-2 family protein 
inhibitor [26] is an example. Two fragments with binding affinities between 300 
and 4,000 µM to the Bcl-xL protein were initially identified by a high-throughput 
NMR-based method. These two fragments bind to distinct, proximal subsites 
within the BH3 peptide binding cleft. The linkage of these two proximal fragments 
and further chemical modification achieved the highly potent Bcl-2 family protein 
inhibitor ABT-737. One of the analogues of this compound, ABT-263, is now in 
clinical trials for the treatment of cancer [26]. 
In silico screening 
In silico screening is an approach using the structural knowledge of a 
protein-protein interface in combination with computational modeling. It has been 
employed to identify PPI inhibitors when the structure of the interaction site is 
known. For instance, a virtual screen was used as the starting point in the search 
for a compound that targets the SH3 binding surface of the HIV type 1 Nef 
protein. High-throughput docking and application of a pharmacophore filter 
identified compounds that were shown to possess micromolar affinity and 
compete with the Nef-SH3 interaction in a cell-based assay [27]. 
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With the exception of HTS, these approaches require additional pre-
existing knowledge of the target protein, specifically the structure of the desired 
target and knowledge of its binding hot-spots. 
3.2.3 Biochemical assays for high-throughput screening  
Unlike the traditional HTS with enzymes as targets, the screening assays 
for protein-protein interactions monitor the binding of two or more proteins, and 
can be used to measure inhibition of the PPIs by small molecules or other 
modulators, such as antibodies or peptides. A growing number of biochemical 
assays have been used for detection and screening of protein-protein 
interactions in HTS. These include fluorescence polarization (FP), 
Fluorescent/Forster resonance energy transfer (FRET), Enzyme-linked 
immunosorbant assays (ELISA) and AlphaLISA [28]. An overview of these assay 
formats is provided in Table 3.1. 
To measure a PPI by ELISA, one of the proteins is attached to a 
stationary surface and the second protein is then allowed to bind to it. The 
second protein is detected by binding of an antibody that is linked to an enzyme. 
ELISA analyses can be very sensitive, because the readout is amplified by the 
use of an enzyme. Further amplification can be achieved by use of multiple 
layers, such as secondary antibodies. Assays of this sort are unlikely to suffer 
from compound interference since the compound is not present in the processing 
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Table 3.1 Overview of different biochemical assays applied in high-throughput 
screening 
Method FP ELISA/DELFIA FRET AlphaScreen 
Size of protein 
and/or 
complex 
Labeldd 
ligand need 
to 
be >1500Da 
and protein 
need to be > 
10kDa 
No limit Distance 
between 
donor and 
acceptor 
need to be 
<9 nm 
Distance 
between donor 
and acceptor 
need to be <9 
nm 
Sensitivity [FP probe] 
~nM [Protein] 
determined 
by Kd of PPI 
Can be as low 
as fg/well 
Depends on 
Kd of PPI, 
typically 1-
100 nM 
Can be as low 
as fg/well 
Washing steps no yes no no 
Signal range 
(high/low) 
3-5 fold 4-5 log <10 fold 2-3 log 
Cost Low -
moderate 
Low - moderate Moderate - 
high 
High 
Advantages Low standard 
deviation, 
direct PPI 
measurement 
Low 
spectroscopic 
interference 
from 
compounds 
Radiometric, 
readily 
controlled 
for spectral 
artifacts 
Monitor the 
widest range of 
complex size 
Disadvantages Interference 
of 
fluorescence 
compounds 
Sensitive to off 
rate, laborious 
Signal 
window 
dependent 
on distance 
and dye 
orientation 
Sensitive to 
ambient light 
 
step. Most ELISAs however require multiple incubation and washing steps, which 
are time-consuming for in automated and bench-top assays. Washing can also 
disrupt weak (Kd > 1 μM) interactions. 
The other three assays, FP, FRET and AlphaLISA, are all mix-and-read in 
nature. There are no additional washing steps required and this leads to a wider 
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dynamic range and higher plate throughput. FRET and AlphaScreen are 
proximity measurements, in that they rely on the protein partners being within 10 
– 90 Ǻ of one another.  
Fluorescent Polarization (FP) measures the tumbling time, which is related 
to its molecular mass, experienced by a fluorophore. It is a sensitive 
nonradioactive method for the study of molecular interactions in solution [29-32] 
and can be used to measure association and dissociation of two molecules if one 
of the molecules is relatively small and fluorescently labeled. When a 
fluorescently labeled molecule is excited by polarized light, it emits light whose 
degree of polarization is inversely proportional to the rate of molecular rotation 
which in turn is largely dependent on molecular mass, with larger masses 
showing slower rotation. Thus, when a small, fluorescent biomolecule, such as a 
fluorescently labeled small peptide or ligand (typically < 1500 Da), is free in 
solution, it will emit low fluorescence polarization, but when bound to a larger 
(e.g. > 10,000 Da) molecule, such as a protein, the rotational movement of the 
fluorophore decelerates and the fluorescence polarization will be highly polarized. 
Thus, the binding of a fluorescently labeled small molecule or peptide to a protein 
can be monitored by the change in polarization. FP-based technology has a 
number of key advantages for monitoring bimolecular interactions, especially for 
HTS applications. It does not involve radioisotopes and employs a homogenous 
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“mix-and-read” format with no wash steps, multiple incubations or separations. 
FP measurement is carried out directly in solution; no perturbation of the sample 
is required, making the measurement faster and more direct than immobilization-
based methods like ELISA and it is readily adaptable to low volumes (30 µl for a 
384-well plate or 5 µl for a 1536-well plate). As a fluorescence-based technology, 
FP is subject to optical interference from compounds that absorb at the excitation 
or emission wavelengths of the fluorescent probe. The method is also sensitive 
to the presence of fluorescence from test compounds but the use of red-shifted 
probes can minimize background fluorescence interference. Since FP assay is 
sensitive, homogeneous and simple, it has been used in primary HTS and 
successfully for identification of small molecules as inhibitors of protein-protein 
interactions [33-36].  
3.2.4 Multiple approaches for validation of HTS hits 
The hits identified by primary HTS have to be validated further and it must 
be decided if they should be pursued further. A high degree of validation is 
recommended for protein-protein interactions, because the targets are typically 
novel in small-molecule discovery research and the initial compounds are often 
hydrophobic with weak activities and having nonspecific binding. Many 
approaches have applied to identification of new compounds that can serve as 
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Figure 3.1 Multiple levels of assays 
for validation and characterization of 
protein-protein interaction inhibitors. 
starting points for further study. Steps which can be used to validate and 
characterize new PPI inhibitors are listed in Figure 3.1.  
Compounds are first identified as hits when they show activity in a primary 
screen (Figure 3.1). To rule out assay-specific artifacts, usually a secondary 
functional assay which uses a different method of detection is employed (Figure 
3.1). Aggregation or irreversible binding of compounds are also issues that must 
be addressed during the validation. Qualitative biophysical assays can be used in 
a screening mode for the direct identification of high-stoichiometry binding or 
unusual binding kinetics. Surface plasmon resonance (SPR) is a very commonly 
used method for qualitative and quantitative examination of protein-compound 
interactions [37, 38] (Figure 3.1). 
For new biological systems, it is 
also useful to measure the 
stoichiometry of the protein-ligand 
interaction and to demonstrate that the 
observed inhibition is related to the 
binding interaction by relating the IC50 
and Kd values. A number of biophysical 
methods are available to address these 
issues. Isothermal calorimetry (ITC) for 
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example, provides a wealth of valuable data, including the Kd, the enthalpy and 
entropy of the interaction and the binding stoichiometry[39]. 
NMR or X-ray crystallographic approaches provide a highly detailed level 
of characterization of the protein-compound interaction site. In addition to 
validating the binding of the small molecule, the binding site characterization can 
have a major impact on compound optimization and often leads to an 
understanding of the mechanisms at play. 
A compound or series of compounds can be considered to be reasonably 
well validated when assay-dependent artifacts, aggregation and irreversible 
binding are ruled out. Biophysical methods, including NMR and X-ray 
crystallography, further allow the researcher to view the binding event itself, 
providing strong, positive evidence that a compound is a bona fide hit. 
3.2.5 Summary 
We have characterized the AF9/ENL-DOT1L protein-protein interaction 
extensively and identified the DOT1L 865-874 10mer peptide as the minimum 
region essential for the AF9/ENL-DOT1L interaction. It was reasoned that the FP 
assay might be particularly appropriate to the study of AF9/ENL-DOT1L protein-
protein interactions because the interaction of the AF9/ENL protein with DOT1L 
is mediated by the well-defined short peptide motifs in DOT1L, which can be 
synthesized and labeled for development using an FP assay.   
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In this study, we first developed a novel FP-based competitive assay, 
which is robust, reliable, cost efficient and reproducible. We performed HTS with 
about 101,000-compounds for small molecule inhibitors of the AF9-DOT1L 
interaction. Of the 101,000 compounds, 4 were found to inhibit the AF9-DOT1L 
PPI in both FP and SPR competitive assays and with further synthetic chemistry 
follow-up, these compounds may lead to inhibitors of the AF9-DOT1L interaction 
useful for both research and therapeutic purposes. 
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3.3 Experimental procedures 
3.3.1 Protein purification and chemical reagents 
The GB1-AF9 (497-568) was expressed in Escherichia coli strain BL21 
(DE3) (Invitrogen). The medium for bacterial growth in all binding studies was 
Luria Broth. The proteins were induced with 200 µM IPTG at 16 °C. The cells 
were harvested after 20 h and resuspended in cold lysis buffer consisting of 50 
mM Tris HCl, pH 7.5, 150 mM NaCl, 0.01 % β-mercaptoethanol and purified by 
affinity chromatography employing Ni-agarose (Qiagen). The proteins were 
further purified with size exclusion chromatography in 50 mM Tris HCl, pH 7.5, 
150 mM NaCl, 3 mM DTT. All purified recombinant proteins were stored at -80 °C 
for further experiments. 
The Triton X-100 was from Sigma (St. Louis, MO). The 10,000 structurally 
diverse chemical compounds were obtained from ChemBridge (San Diego, CA) 
as part of the collection of the University of Michigan Center for Chemical 
Genomics (CCG). 
3.3.1.1 Synthesis of fluorescein labeled DOT1L peptides 
The fluorescein-labeled peptides N-Flu and C-Flu were synthesized 
according to the standard Fmoc protocols described in Chapter 2 (2.3.3). For 
fluorescein labeling, resin-bound peptides were treated with 1 % TFA/DCM to 
selectively remove the Mtt protective group from the lysine side chain. The 
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peptide was then treated with solution of 5-carboxyfluorescein (5-FAM) N-
hydroxysuccinimidyl ester, HATU, HOAt, and DIEA in NMP, and then washed with 
DCM and MeOH. The reaction mixture was covered in aluminum foil and mixed 
by being rocked on a Clay Adams Nutator for 2 h. Finally, the peptide was 
removed from the resin and simultaneously the side-chain was deprotected with 
87.5 % TFA, 5 % DTT, 5 % H2O, and 2.5% TIS at room temperature for 2 h. The 
crude peptides were purified by semi-preparative reverse-phase high-
performance liquid chromatography (RP-HPLC model of HPLC). Peak fractions 
were concentrated and lyophilized for 16−24 h. The pure peptides were 
characterized by analytical RP-HPLC and electrospray ionization mass 
spectrometry (ESI-MS). The purity of all fluorescent peptides was over 98 %, 
based on their HPLC and mass spectral data. 
3.3.2 Determination of the equilibrium dissociation constant (Kd) of Flu-
DOT1L peptides with GB1-AF9  
Fluorescence polarization experiments were performed in Dynex 96-well, 
black, round-bottom plates (Fisher Scientific) using a plate reader (Biotek H1 
hybrid). To each well, fluorescein-labeled DOT1L peptides (10 nM final ) and 
increasing concentrations of GB1-AF9 protein (from 0 to 24 µM) were added to a 
final volume of 125 µL in the assay buffer (100 mM Na2HPO4, pH 7.5, 150 mM 
NaCl, 0.01 % Triton X-100). The plate was mixed on a shaker and incubated at 
room temperature for 3 h to reach equilibrium. The polarization values in milli-
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polarization units (mP) were measured at an excitation wavelength at 485 nm 
and an emission wavelength at 530 nm. To test the assay stability, a plate was 
measured at different times over a 24 h period. To determine the effect of DMSO 
on the assay, binding experiments were performed under conditions with or 
without 4 % DMSO in the assay buffer described above. For the effects of the 
reducing reagent, binding experiments were performed with or without 0.1 % β-
mercaptoethanol. Experimental data were analyzed with Prism 5.0 software 
(GraphPad Software, San Diego, CA). 
3.3.3 Competitive binding experiments 
The corresponding unlabeled DOT1L peptides, including DOT1L-16mer, -
10mer and -7mer, were tested for their ability to displace the N-Flu DOT1L 
fluorescent probe from GB1-AF9. Negative controls containing GB1-AF9 and 
probe (equivalent to 0 % inhibition), and positive controls containing only free N-
Flu DOT1L peptide (equivalent to 100 % inhibition), were included on each assay 
plate. The dose-dependent binding experiments were carried out with serial 
dilutions of peptides, prepared in DMSO. A 5 µL sample of the tested samples 
and pre-incubated GB1-AF9 protein (500 nM) and N-Flu DOT1L peptide (10 nM) 
in the assay buffer were added in 96-well plates to produce a final volume of 125 
µL. The polarization values were measured after 3 h incubation and IC50 values 
were determined from the plot by nonlinear least-squares analysis. 
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The Ki values of competitive inhibitors were calculated using the equation 
described previously [40] based upon the measured IC50 values, the Kd value of 
the probe and GB1-AF9 complex, and the concentrations of the protein and 
probe in the competitive assay. 
The SPR based competitive assay is described in Chapter 2. 
3.3.4 High-Throughput Screening of AF9-DOT1L interaction 
Using a Multidrop 384 (Thermo Scientific, Waltham, MA), assay buffer was 
added to each well of a low-volume black 384-well plate (Cat. 3676, Corning, NY). 
The assay buffer (10 µL) was added first to the wells then, using a 384-well pin 
tool on a Biomed FX liquid-handling workstation (Beckman Coulter, Fullerton, CA) 
200 nL of compounds (stock concentration 2 mM) or DMSO for control wells, 
were added, producing a final compound concentration of 20 µM and 1 % DMSO. 
10 µL of 2X GB1-AF9 and Flu-DOT1L complex, producing final concentrations of 
500 nM GB1-AF9 and 10 nM Flu-DOT1 were added to the wells by Multidrop. 
Plates were incubated at room temperature for 1 h, then read for fluorescence 
polarization with a PHERAstar (BMG LabTech, Offenburg, Germany) plate 
reader with wavelengths of 485 nm for excitation, and 525 nm for emission. For 
follow-up dose-response studies of the primary hits, the same method as for the 
primary screen was performed, except that compounds were first added to the 
wells of the 384-well plate using serial of 1.67-fold dilution over a range of 
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concentrations between 150 µM and 4.2 µM, and the buffer and 2X complex 
were added to the wells. The chemical structures of confirmed hits were 
analyzed and clustered for which a 65% or greater similarity was used for their 
clustering by the software Tripos BenchWare DataMiner.  
3.3.5 Data calculations 
To evaluate the quality and suitability of the AF9-Dot1L fluorescence 
polarization assay for high-throughput screening, we determined the Z‟ factor, 
which is an indicator of the viability of the assay for screening, by incorporating 
the precision of the assay [41]: 
𝑍′ = 1 −
(3𝑆𝐷𝑓 + 3𝑆𝐷𝑑)
(µ𝑏 − µ𝑓)
 
where SDf and SDd are the standard deviation of the signal (mP) for free and 
bound probe, respectively, µb represents the mean of the signal obtained for the 
bound probe in the absence of a competitive inhibitor, and µf is the mean of the 
free probe in the absence of the GB1-AF9 protein. 
  
  
103 
 
 
 
Figure 3.2 Schematic illustration of the Fluorescence Polarization and Surface 
plasmon Resonance (SPR) based competitive assay. (A) FP competitive assay (B). 
SPR competitive assay. 
 
3.4 Results  
3.4.1 Assay principles 
 Following previous studies, we devised a homogeneous fluorescence 
polarization assay based on binding of recombinant soluble GB1-AF9 protein to a 
synthetic DOT1L 10mer peptide conjugated with a fluorescein (Flu-DOT1L) 
(Figure 3.2A).  
In this FP assay, the rotation of Flu-DOT1L peptide slows down upon 
binding to the GB1-AF9 protein, thus affecting the polarization of the Flu-DOT1L 
peptide. Compounds that displace this Flu-DOT1L peptide from the AF9 protein 
cause a change in the FP of the sample, and this change is used to quantify the 
binding. The FP assay can be used in a high-throughput format to identify small 
molecule leads that inhibit the AF9-DOT1L interaction. 
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However, fluorescence from the compounds library can cause artifacts 
and accordingly, surface plasmon resonance (SPR) assay was established as a 
secondary approach to conﬁrm speciﬁcity of the interruption of AF9-DOT1L 
interaction (Figure 3.2B). The DOT1L protein was immobilized on a sensor chip 
and AF9 protein ﬂowing in the mobile phase over the protein immobilized protein 
gives a high refractive signal (Figure 3.2B). When small molecules bind to the 
AF9 protein and block the binding of AF9 protein with DOT1L, the refractive 
signal will be reduced. It had been shown that the DOT1L 10mer peptide 
competes readily with the immobilized DOT1L protein for binding to AF9 protein 
with IC50 = 0.49 µM (Figure 2.6A), and this indicates that the SPR-based 
competitive assay will be an effective method to gain independent conﬁrmation of 
the speciﬁcity of compounds identiﬁed by the ﬂuorescence polarization assay. 
3.4.2 Design, synthesis and characterization of fluorescein DOT1L 
peptides 
We synthesized two different fluorescent probes using fluorescein as a 
fluorophore (Figure 3.3): the N-terminal fluorescein-labeled DOT1L peptide with 
the sequence Ac-K(FAM)(β)A(β)ALPISIPLSTV-NH2 termed N-Flu-DOT1Ll; the C-
terminal DOT1L fluorescein labeled DOT1L peptide with the sequence Ac-
LPISIPLSTV(β)A(β)AK(FAM)-NH2. These two fluorescent probes were first 
tested in a saturation binding experiment to determine their binding affinity to AF9 
C-terminal domain (Figure 3.4). 
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Figure 3.3 Structure of two fluorescein 
labeled DOT1L peptides. 
 
Figure 3.4 Saturation of  GB1-AF9 with different 
fluorescent probes. The fluorescein DOT1L 
peptides is 10 nM and GB1-AF9 is in the range of   
0 to 24 µM.  
 The dissociation constant (Kd) for each protein/peptide pair was 
determined using a constant 
concentration of probe and 
titrating with the GB1-AF9 (497-
568) protein. The two tested 
probes showed binding and the 
FP values of the peptides 
increased as a function of GB1-
AF9 protein concentration. The Kd 
of binding between the N-Flu-DOT1Ll probe and GB1-AF9 was determined to be 
46 nM with a dynamic range of 128 mP. The C-Flu-DOT1L peptide showed a 
slightly decreased binding 
affinity as the N-Flu-DOT1L 
peptide, with a Kd of 141 nM, 
and a much narrower dynamic 
range of 80 mP. Based on the 
information obtained in 
saturation experiments, the Kd 
values and dynamic binding 
ranges, we chose to use the 
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Figure 3.5 Effect of probe peptide concentration on assay performance. (A) 
Fluorescence polarization and total fluorescence of different concentration of Flu-
DOT1L probe (2.5 – 80 nM) alone or in complex with GB1-AF9 (500 nM). (B) 
Saturation of GB1-AF9 protein with different concentration of Flu-DOT1L probe (5 nM 
and 10 nM).  
N-Flu-DOT1L peptide as the probe for further development and optimization of 
the FP-based assay for GB1-AF9.  
To demonstrate that the FP is independent of the total fluorescence, N-
Flu-DOT1L (2.5 – 80 nM) was titrated against a constant GB1-AF9 concentration 
(500 nM) (Figure 3.5A).  
The data summarized in Figure 3.5A show a linear increase in total 
fluorescence with increasing concentration of N-Flu-DOT1L, whereas the FP 
signal with N-Flu-DOT1L peptide alone, or N-Flu-DOT1L peptide in complex with 
the GB1-AF9 protein, remain constant. Additionally, saturation of the GB1-AF9 
protein with different concentrations of the N-Flu-DOT1L peptide (5 nM and 10 
nM) gives similar Kd values (56 nM and 72 nM respectively) (Figure 3.5B). It was 
concluded that the FP signal is independent of the probe concentration and a 10 
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nM concentration of the Flu-DOT1L peptide was selected for the FP assay 
optimization. 
3.4.3 Stability and specificity of the FP assay 
The stability of the AF9 FP assay, critical for high-throughput screening, 
was tested by incubating the plate at room temperature over a 24 h period, 
reading the plate several times, and analyzing the data. The results obtained 
showed that the assay is stable, as evidenced by the binding curves (Figure 
3.6A). The obtained Kd values and the binding ranges remained unchanged over 
a 24-hour time period. We also tested the influence of DMSO, a commonly used 
solvent, in high-throughput screening. The results obtained showed that the 
binding affinity and dynamic range of N-Flu-DOT1L probe are unchanged in the 
presence of 4 % DMSO (Figure 3.6B) The DMSO tolerance renders this assay 
suitable for high-concentration (i.e. 100 μM) screening campaigns where 4 % 
DMSO is necessary to help minimize solubility issues of library compounds. The 
effects of reducing reagent were also tested, as shown in Figure 3.6C. In the 
presence of 0.1 % β-mercaptoethanol, the binding affinities of N-Flu-DOT1L 
peptide to GB1-AF9 are not affected. We also test the specificity of the assay by 
titrating GB1 tag protein with N-Flu-DOT1L peptide (Figure 3.6D). The GB1 tag 
failed to bind to the DOT1L peptide, indicating that the FP assay is specific and 
unaffected by the fusion tag.  
  
108 
 
 
 
Figure 3.6 Stability and specificity of GB1-AF9 FP assay. (A) Saturation 
experiment with N-Flu-DOT1L to monitor the Kd and dynamic range over an 
extended time period. N-Flu-DOT1L (5 nM) was titrated with GB1-AF9 (0.04 nM 24 
µM) in assay buffer (100 mM NaH2PO4, pH 7.4, 150mM NaCl, 0.01% Triton X-100) 
containing 4 % DMSO and the plate was read at the indicated time points. (B) 
Saturation experiments with N-Flu-DOT1L to determine the effect of DMSO. 
Experiments were performed as in (A) in the presence of 0  or  4 %  DMSO.  (C)  
Saturation  experiments  with  N-Flu-DOT1L  to determine  the  effect  of  adding 
detergent  to  the  assay  buffer.  Saturation experiments  were  performed  as  in  
(A)  using  assay  buffers  containing  0,  0.1 % β-ME in the presence of 4 % 
DMSO. (D) Saturation experiments of N-Flu-DOT1L with GB1-AF9 or GB1 tag to 
determine the effect fusion tag on the binding assay.  Saturation experiments were 
performed as in (A) using assay buffer containing 4 % DMSO. 
All the above tests indicate that fluorescence polarization assay of GB1-
AF9 and the N-Flu-DOT1L peptide is stable, specific and robust, and adequate 
for high-throughput screening.  
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3.4.4 Validation of the FP assay with known DOT1L peptide antagonists 
An FP-based competitive assay is used to screen compounds and 
typically uses standard concentrations of protein and fluorescence probes, with 
various concentrations of inhibitors. The concentrations of the fluorescence 
tracer and the protein used in the FP-based assay should be chosen carefully 
with a view to maximizing the difference between the highest and lowest 
polarization values and increasing the sensitivity of the assay. FP competition 
experiments are best designed such that the [receptor]/Kd ratio is at least 1, and 
the starting polarization value represents approximately 50 % of the maximal FP 
change observed in the saturation experiment. We chose to use a concentration 
of 10 nM for the probe. This is a concentration which has high fluorescence 
intensity and can overcome the potential interference of any weakly fluorescent 
compounds. To determine the optimal concentration of the protein, we evaluated 
three different concentrations (250, 500 and 1000 nM) of the GB1-AF9 with a 
fixed concentration (10 nM) of N-Flu-DOT1L in the competitive binding assay to 
determine the IC50 value and Ki of the DOT1L 10mer peptide (Figure 3.7A).  
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Figure 3.7 Optimizaion of FP competitive assays. (A) Displacement of N-Flu Dot1l 
probe from GB1-AF9 by DOT1L 16mer peptide using three protein concentrations. 
Increasing protein concentration increases the dynamic range of the assay but also 
increases the IC50. (B) Test of different DOT1L peptides by competitve assay with 
500nM GB1-AF9 protein and 10 nM Flu-DOT1L peptide and various concentrations of 
peptides. The IC50 and Ki values of each peptides are indicated. 
Using 250 nM, 500 nM and 1000 nM (5-, 10- or 20- fold the Kd), as the 
protein concentration, the dynamic ranges of the assay were 75∆mP, 87∆mP and 
100∆mP, respectively (Figure 3.7A). With higher protein concentrations, the IC50 
values obtained for the competitors were increased. There is a good correlation 
between the observed IC50 values and concentrations of the protein used in the 
assay (Figure 3.7A). The IC50 values obtained for these peptides are significantly 
higher than the Kd values of corresponding fluorescent labeled peptide tracers, 
but the rank order is the same under all conditions. The Ki values for the DOT1L 
10mer under different concentrations of GB1-AF9 proteins were calculated as 
reported previously [40]. As expected, Ki values of the DOT1L 10mer peptides 
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are similar with these different GB1-AF9 protein concentrations, and are close to 
the Kd of the Flu-DOT1L with the protein (Figure 3.7A). We chose 500 nM as the 
concentration of the GB1-AF9 protein for the competitive binding assay because 
this is about 10-fold of the actual Kd value (Figure 3.4) and at this concentration a 
majority of the fluorescent probe will be bound to the protein.  
To further validate the optimized FP-based competitive binding assay 
conditions, we tested three corresponding unlabeled peptides: DOT1L 16mer, 
DOT1L 10mer and DOT1L 7mer, with different binding affinities to the AF9 
protein (Figure3.7B). The Ki values for these peptides were calculated and as 
expected, DOT1L 16mer and DOT1L 10mer peptide have similar binding 
affinities (Ki = 7.6 nM for DOT1L 16mer and 26.6 nM for DOT1L 10mer). DOT1L 
7mer has weak binding affinity (Ki = 428 nM). 
These validation experiments provide evidence that the FP competitive 
binding assay will quantitatively and accurately determine the binding affinities of 
small-molecule inhibitors with different binding affinities to the GB1-AF9 protein. 
The optimized 96-well format assay is robust and sensitive (Z‟ factor of 0.79) and 
suitable for using it in the high-throughput screening. 
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Figure 3.8 Calculated Z’ factor in (A) 384-well and (B) 1536-well plate. The 
polarization signal of the free Flu-DOT1L peptide (10 nM) is in blue and the bound 
peptide (500 nM GB1-AF9 and 10 nM Flu-DOT1L) is in red. 
3.4.5 High-throughput format development and miniaturization  
The simple one-step “mix-and-measure” format of the AF9 and DOT1L FP 
assay and its demonstrated sensitivity allow this method to be used for 
automated operation in HTS approach for identifying small-molecule inhibitors of 
this PPI. In order to use the FP based optimized assay, the reaction volume has 
to be scaled down for performing the screening in low volume 384-well plates, a 
total volume of 20 μL. To test the utility of this HTS format, we examined the 
precision and robustness of the assay (Figure 3.8A).  
For this purpose, each microplate contained an identical set of control 
reactions as the following: 1) Positive control represented by free Flu-DOT1L 
peptide (10 nM) which give minimal mP signal that corresponds to 100% 
inhibition, 2) Flu-DOT1L peptide (10 nM) in complex with GB1-AF9 (500 nM) 
giving the maximum signal and represents negative control for 0 % inhibition. 
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This test also provides an experimental basis for setting the operational threshold 
to identify potential positives in the primary screenings. One of the parameters for 
determining the quality of a high-throughput assay is the Z‟ factor, a statistical 
parameter that assesses the performance of HTS assays [42]. The Z‟ factor is 
reflective of both the assay dynamic range and the data variation. Assays with 
small Z‟ factors are not suitable for high-throughput screening and require further 
optimization, while assays with Z‟ factors close to the maximum value of 1 are of 
high quality. The calculated Z′ factor of the FP assay in 384-well format is 0.72, 
demonstrating a robust and consistent assay with minimal variability (Figure 
3.8A). Thus, the FP assay for AF9 binding based on Flu-DOT1L peptide is of 
excellent quality for HTS.  
The ability to perform primary screening assays in high-density micro-well 
plates at low volumes (1-5 µL) is important to accelerate the early stages of drug 
discovery and reduce costs. The AF9-DOT1L FP assay was successfully 
miniaturized to 1536-well format using 4 µL total volumes, significantly reducing 
reagent consumption, without compromising assay reliability. Z' factor value 
determined for the FP assay in 1536-well format was found to be 0.65 (Figure 
3.8B), confirming the assay to be robust, reliable, and suitable for HTS purposes.  
 
  
114 
 
 
 
Figure 3.9 Fluorescence polarization screen for inhibitors of AF9-DOT1L interaction. 
(A) Schematic of the HTS process.(B) Control  samples  run  on  each  plate  include  
10 nM Flu-DOT1L and 500nM GB1-AF9 complex as  a  negative  (0 %  inhibition)  
control  (•)  and  Flu-DOT1L only  as  a  positive  (100 %  inhibition)  control  (•).  The 
statistical Z‟ Factor measurement for the HTS was calculated to be 0.68 for this entire 
screen indicating suitable reproducibility.  (C)  Data  from  the  101,000  compound  
HTS are  shown  (•)  with  a  3 standard deviation  line indicated in red.  
3.4.6 HTS for identification inhibitors of the AF9/DOT1L protein-protein 
interaction 
 Using our optimized AF9-competitive FP binding assay and DOT1L-
10mer peptide as the fluorescent probe, in-house library of 101,000 structurally 
diverse small molecules were screened at the Center for Chemical Genomics at 
the University of Michigan. Primary screening of these compounds at a single 
concentration of 20 µM identified 1,191 potential active compounds with inhibition 
larger than 3 standard deviations above the negative control giving a hit rate of 
1.2 % (Figure 3.9A and C).  
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Figure 3.10 HTS Identified compounds structures. (A) Five classes of compounds 
with different scaffolds. (B) Structures of identified singleton compounds. 
The Z‟ factor for the primary screen was determined to be 0.68 (Figure 3.9B), the 
signal-to-noise was 19 and the coefficient of variation value was 0.08, indicating 
the quality and reproducibility of the used FP assay.  
The 1191 compounds were further tested using the same conditions as in 
the primary screen and 164 compounds were confirmed, after removing the 
autofluorescent compounds,  quenchers and compounds with reactive functional 
groups (14 % confirmation rate, 0.16 % overall). These 164 compounds were 
chosen for dose-response confirmation using concentration range from 4-150 µM 
with compound stocks directly from the mother plates. Thirty nine compounds 
demonstrated dose-dependent inhibition in the FP assay.  
  
116 
 
 
 
Figure 3.11 Dose-response FP competitive binding curves of active compounds. 
The analysis of the chemical structures of these 39 compounds showed 
that they can be classified into five clusters by Tripos BenchWare DataMiner  
with different chemical scaffolds and the rest of the compounds have unique 
structures (Figure 3.10).  
3.4.7 Validation of HTS identified compounds 
One of the most important steps after performing HTS approach for 
identifying small-molecule modulator of protein function is the follow-up of the 
obtained hits and their characterization and validation into high-content lead 
series. 
Based on the potency, chemical structure and availability of these 39 
compounds, 8 compounds were purchased and new stock solutions were 
prepared. Their chemical structures were confirmed by NMR or LC-MS and re-
tested using the FP based binding assay. Four of these compounds, belonging to 
  
117 
 
 
the chemical clusters I, IV and V, demonstrated reproducible dose-dependent 
inhibition against AF9-DOT1L interaction with IC50 from 10 – 50 µM (Figure 3.11), 
confirming the results obtained in HTS. The Hill slopes of competitive curve for 
these four compounds are between 1-2. 
One compound did not show any binding and was not confirmed as a binder. The 
other three compounds showed higher fluorescence of the Flu-DOT1L-10mer 
peptide used in the assay, making them not appropriate to be tested and 
determined their binding affinity with FP assay because of the potential 
interference with the assay. 
3.4.8 Orthogonal testing with biophysical methods 
In order to further validate the binding of the four confirmed compounds 
and identify potential promiscuous inhibitors, several secondary assays have 
been developed to support hit confirmation and the hit-to-probe optimization 
process. Using the FP based assay, we showed that the compounds were able 
to compete off the fluorescent-labeled DOT1L peptide from AF9 protein. In order 
to determine that the compounds bind effectively to the target and disrupt 
protein-protein interaction, SPR competitive binding assay was used. This assay 
use different platform that the FP based assay where DOT1L protein is 
immobilized on CM5 chip and allows testing the inhibitors for their ability to 
disrupt AF9-DOT1L interaction. The four compounds confirmed in FP were 
  
118 
 
 
 
Figure 3.12 Dose-response SPR competitive binding curves of active 
compounds 
further validated and showed similar potency in disrupting the PPI with IC50 from 
15 to 79 µM (Figure 3.12) as in the FP based assay.  
NMR spectroscopy has been successfully utilized to detect binding of 
small-molecule compounds to large biomolecules and in the last decade many 
new NMR-based screening methods have been established to characterize the 
binding processes. Therefore, confirmed hit compounds in two different binding 
assays, FP and SPR, were further tested using Saturation Transfer Difference 
(STD) NMR experiments [43]. The purpose of this assay is to provide further 
validation of the hit selection in addition to the biochemical assays by verification 
of direct binding of the compounds to AF9 protein. This technique is the most 
direct measure of inhibiting the AF9-DOT1L interaction by a small molecule and 
is allowing characterization of the binding interactions at an atom level, termed 
group epitope mapping (GEM). A strong STD effect was observed for compound 
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38 and weaker STD signals for compound 36, indicative of their direct binding to 
AF9 (Figure 3.13). Compounds 32 and 37 were also tested but because of their 
limited solubility we were not able to perform this experiment. 
Overall these data demonstrate the feasibility of development of small 
molecules targeting C-terminal hydrophobic domain in AF9, indicating it is a 
“druggable” target. These data demonstrate that our FP-based assay is suitable 
for high-throughput screening and for the first time, we have shown that it is 
possible to discover non-peptide small-molecules that can block the interaction 
between DOT1L and AF9. This is an important initial proof-of-concept for the 
development of small molecules targeting C-terminal hydrophobic domain in AF9, 
indicating it is a “druggable” target.    
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Figure 3.13 STD NMR experiments with compounds 36 (A) and 38 (B). Top 
spectrum represents 1D STD spectrum of tested compound (200 μM) in complex 
with AF9 (5 μM) and the bottom spectrum is 1D NMR spectrum.  
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3.5 Discussion 
First, we synthesized two fluorescein labeled DOT1L peptides and tested 
the binding of these peptides with GB1-AF9 protein (Figure 3.4). The N-terminal 
fluorescein labeled DOT1L peptide showed better dynamic range and binding 
affinity compared to the C-terminal fluorescein labeled peptide, and was used for 
the FP assay development. The binding affinity for the GB1-AF9 and Flu-DOT1L 
peptide was 42 ± 16 nM (Figure 3.4), which is consistent with the Kd between 
AF9 and DOT1L protein determined by SPR (Table 2.1). These results 
demonstrate that the AF9-DOT1L protein interaction could accurately be 
detected and quantitated by FP assay. Second, the competition binding 
experiment results demonstrated that the Flu-DOT1L peptide could be displaced 
by the unlabeled DOT1L peptides (Figure 3.7). This was important as it 
demonstrates specificity of the Flu-DOT1L interaction with GB1-AF9 and also 
showed that the assay can be used to search for compounds that disrupt AF9-
DOTL1L interaction. Third, because of its excellent stability, DMSO tolerance, 
and simplicity, in 384-well plate format, the developed FP assay has a Z‟ factor of 
0.72 (Figure 3.8A), making this FP assay is particularly suited for HTS. 
Furthermore, the assay was miniaturized to a volume of 5 µL with excellent 
performance (Figure 3.8B), suggesting a possibility of adapting it to a 1536-well 
plate format for ultra-HTS of small-molecule AF9-DOT1L interaction inhibitors. 
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Using our HTS optimized FP-competitive assay, we screened of 10,1000 
compounds at the Center for Chemical Genomics at the University of Michigan. 
Our first round of screening identified 1191 potential active compounds. After 
confirmation screening and dose-response experiments we were left with 39 
compounds that required further follow up. Eight compounds were obtained from 
commercial sources and four showed confirmed dose-dependent inhibition in our 
FP and SPR competitive assay (Figure 3.11 and 3.12). Of these four compounds, 
CCG-186912 (IC50 = 12.1 μM) and CCG-186911 (IC50 = 31.1 µM) belong to the 
same class and both demonstrated dose-dependent inhibition in both our FP 
assay and SPR-based secondary assay (Figure 3.11 and 3.12).  
 
 
 
 
 
  
  
123 
 
 
3.6 References 
1. Arkin, M., Protein-protein interactions and cancer: small molecules going 
in for the kill. Curr Opin Chem Biol, 2005. 9(3): p. 317-24. 
2. White, A.W., A.D. Westwell, and G. Brahemi, Protein-protein interactions 
as targets for small-molecule therapeutics in cancer. Expert Rev Mol Med, 
2008. 10: p. e8. 
3. Blazer, L.L. and R.R. Neubig, Small molecule protein-protein interaction 
inhibitors as CNS therapeutic agents: current progress and future hurdles. 
Neuropsychopharmacology, 2009. 34(1): p. 126-41. 
4. Whitty, A. and G. Kumaravel, Between a rock and a hard place? Nat 
Chem Biol, 2006. 2(3): p. 112-8. 
5. Wells, J.A. and C.L. McClendon, Reaching for high-hanging fruit in drug 
discovery at protein-protein interfaces. Nature, 2007. 450(7172): p. 1001-9. 
6. Jones, S. and J.M. Thornton, Principles of protein-protein interactions. 
Proc Natl Acad Sci U S A, 1996. 93(1): p. 13-20. 
7. Lo Conte, L., C. Chothia, and J. Janin, The atomic structure of protein-
protein recognition sites. J Mol Biol, 1999. 285(5): p. 2177-98. 
8. Cheng, A.C., et al., Structure-based maximal affinity model predicts small-
molecule druggability. Nat Biotechnol, 2007. 25(1): p. 71-5. 
9. Smith, R.D., et al., Exploring protein-ligand recognition with Binding 
MOAD. J Mol Graph Model, 2006. 24(6): p. 414-25. 
10. Hopkins, A.L. and C.R. Groom, The druggable genome. Nat Rev Drug 
Discov, 2002. 1(9): p. 727-30. 
11. Thompson, A.D., et al., Fine-tuning multiprotein complexes using small 
molecules. ACS Chem Biol, 2012. 7(8): p. 1311-20. 
12. Clackson, T. and J.A. Wells, A hot spot of binding energy in a hormone-
receptor interface. Science, 1995. 267(5196): p. 383-6. 
13. Clackson, T., et al., Structural and functional analysis of the 1:1 growth 
hormone:receptor complex reveals the molecular basis for receptor affinity. 
J Mol Biol, 1998. 277(5): p. 1111-28. 
14. Thanos, C.D., W.L. DeLano, and J.A. Wells, Hot-spot mimicry of a 
cytokine receptor by a small molecule. Proc Natl Acad Sci U S A, 2006. 
103(42): p. 15422-7. 
15. Moreira, I.S., P.A. Fernandes, and M.J. Ramos, Hot spots--a review of the 
protein-protein interface determinant amino-acid residues. Proteins, 2007. 
68(4): p. 803-12. 
16. Bogan, A.A. and K.S. Thorn, Anatomy of hot spots in protein interfaces. J 
Mol Biol, 1998. 280(1): p. 1-9. 
17. DeLano, W.L., Unraveling hot spots in binding interfaces: progress and 
challenges. Curr Opin Struct Biol, 2002. 12(1): p. 14-20. 
  
124 
 
 
18. Ma, B., et al., Protein-protein interactions: structurally conserved residues 
distinguish between binding sites and exposed protein surfaces. Proc Natl 
Acad Sci U S A, 2003. 100(10): p. 5772-7. 
19. Arkin, M.R. and J.A. Wells, Small-molecule inhibitors of protein-protein 
interactions: progressing towards the dream. Nat Rev Drug Discov, 2004. 
3(4): p. 301-17. 
20. Wilson, A.J., Inhibition of protein-protein interactions using designed 
molecules. Chem Soc Rev, 2009. 38(12): p. 3289-300. 
21. Vagner, J., H. Qu, and V.J. Hruby, Peptidomimetics, a synthetic tool of 
drug discovery. Curr Opin Chem Biol, 2008. 12(3): p. 292-6. 
22. Karatas, H., et al., High-affinity, small-molecule peptidomimetic inhibitors 
of MLL1/WDR5 protein-protein interaction. J Am Chem Soc, 2013. 135(2): 
p. 669-82. 
23. Mayr, L.M. and P. Fuerst, The future of high-throughput screening. J 
Biomol Screen, 2008. 13(6): p. 443-8. 
24. Degterev, A., et al., Identification of small-molecule inhibitors of interaction 
between the BH3 domain and Bcl-xL. Nat Cell Biol, 2001. 3(2): p. 173-82. 
25. Vassilev, L.T., et al., In vivo activation of the p53 pathway by small-
molecule antagonists of MDM2. Science, 2004. 303(5659): p. 844-8. 
26. Oltersdorf, T., et al., An inhibitor of Bcl-2 family proteins induces 
regression of solid tumours. Nature, 2005. 435(7042): p. 677-81. 
27. Betzi, S., et al., Protein protein interaction inhibition (2P2I) combining high 
throughput and virtual screening: Application to the HIV-1 Nef protein. 
Proc Natl Acad Sci U S A, 2007. 104(49): p. 19256-61. 
28. Arkin, M.R., et al., Inhibition of Protein-Protein Interactions: Non-Cellular 
Assay Formats, in Assay Guidance Manual, G.S. Sittampalam, et al., 
Editors. 2004: Bethesda (MD). 
29. Checovich, W.J., R.E. Bolger, and T. Burke, Fluorescence polarization--a 
new tool for cell and molecular biology. Nature, 1995. 375(6528): p. 254-6. 
30. Jameson, D.M. and W.H. Sawyer, Fluorescence anisotropy applied to 
biomolecular interactions. Methods Enzymol, 1995. 246: p. 283-300. 
31. Heyduk, T., et al., Fluorescence anisotropy: rapid, quantitative assay for 
protein-DNA and protein-protein interaction. Methods Enzymol, 1996. 274: 
p. 492-503. 
32. Lundblad, J.R., M. Laurance, and R.H. Goodman, Fluorescence 
polarization analysis of protein-DNA and protein-protein interactions. Mol 
Endocrinol, 1996. 10(6): p. 607-12. 
33. Knight, S.M., et al., A fluorescence polarization assay for the identification 
of inhibitors of the p53-DM2 protein-protein interaction. Anal Biochem, 
2002. 300(2): p. 230-6. 
  
125 
 
 
34. Glover, C.J., et al., A high-throughput screen for identification of molecular 
mimics of Smac/DIABLO utilizing a fluorescence polarization assay. Anal 
Biochem, 2003. 320(2): p. 157-69. 
35. Kenny, C.H., et al., Development of a fluorescence polarization assay to 
screen for inhibitors of the FtsZ/ZipA interaction. Anal Biochem, 2003. 
323(2): p. 224-33. 
36. Roehrl, M.H., J.Y. Wang, and G. Wagner, Discovery of small-molecule 
inhibitors of the NFAT--calcineurin interaction by competitive high-
throughput fluorescence polarization screening. Biochemistry, 2004. 
43(51): p. 16067-75. 
37. Rich, R.L. and D.G. Myszka, Survey of the year 2000 commercial optical 
biosensor literature. J Mol Recognit, 2001. 14(5): p. 273-94. 
38. Day, Y.S. and D.G. Myszka, Characterizing a drug's primary binding site 
on albumin. J Pharm Sci, 2003. 92(2): p. 333-43. 
39. Leavitt, S. and E. Freire, Direct measurement of protein binding energetics 
by isothermal titration calorimetry. Curr Opin Struct Biol, 2001. 11(5): p. 
560-6. 
40. Nikolovska-Coleska, Z., et al., Development and optimization of a binding 
assay for the XIAP BIR3 domain using fluorescence polarization. Anal 
Biochem, 2004. 332(2): p. 261-73. 
41. Blevitt, J.M., et al., A Fluorescence-Based High Throughput Screen for the 
Transporter Associated with Antigen Processing. J Biomol Screen, 1999. 
4(2): p. 87-91. 
42. Pope, A.J., U.M. Haupts, and K.J. Moore, Homogeneous fluorescence 
readouts for miniaturized high-throughput screening: theory and practice. 
Drug Discov Today, 1999. 4(8): p. 350-362. 
43. Mayer, M. and B. Meyer, Group epitope mapping by saturation transfer 
difference NMR to identify segments of a ligand in direct contact with a 
protein receptor. J Am Chem Soc, 2001. 123(25): p. 6108-17. 
 
 
  
  
126 
 
 
Chapter 4  
Conclusions and Future Directions 
4.1 MLL fusion oncogenes and DOT1L  
Over the past 20 years, MLL has received much attention and has been 
extensively studied for its pathological mechanism in leukemia development. 
Leukemias bearing rearrangements of the MLL gene are of particular interest 
because of their unique clinical and biological characteristics and poor prognostic. 
MLL translocations found in leukemia generate fusions that encode an N-terminal 
fragment of MLL linked to a C-terminal fragment of various fusion partners [1]. 
The translocation partners are highly diverse and more than 60 known fusion 
proteins of MLL have been identified. The most frequent translocations generate 
the MLL-AF9, MLL-ENL, MLL-AF4, MLL-AF10 and MLL-AF6 fusion proteins in 
leukemias. The extensive studies in past several years have clearly 
demonstrated that fusions of MLL induce widespread epigenetic dysregulation 
that may mediate their transforming activity.  The histone methyltransferase 
DOT1L, which methylates histone 3 on lysine 79 (H3K79), is one of the identified 
binding partners of MLL-fusion oncogenes [2-5]. It was demonstrated that 
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transformation in MLL-rearranged leukemias is driven by a DOT1L dependent, 
aberrant epigenetic program. [6].  MLL fusion proteins, including AF9, ENL, AF10 
and AF17 have been shown to physically interact with DOT1L and recruit DOT1L 
to MLL target downstream genes. A suggested general mechanism by which 
DOT1L contributes to the leukemogenesis process is shown in Figure 1.3 and 
can be described as interaction between DOT1L and MLL fusion partners leading 
to mistargeting of DOT1L to the gene targets of MLL fusion proteins, such as the 
Hoxa cluster and Meis1. Aberrant hypermethylation of H3K79 leads to 
constitutive transcriptional activation of these genes, which in turn results in 
leukemic transformation.  
DOT1L is a validated therapeutic target and its crucial role in MLL-
rearranged leukemias is now well established [7-9]. Proof-of-concept studies 
have recently been reported, using small-molecule inhibitors targeting the 
catalytic domain of DOT1L [9]. EPZ004777, a potent selective inhibitor of 
DOT1L, blocks cellular H3K79 methylation, inhibits leukemogenic gene 
expression, and selectively kills cultured cells bearing MLL translocations. 
However global inhibition of DOT1L function could have major deleterious effects 
in normal hematopoietic stem cells (HSCs) and other tissues, in particular 
cardiac function.  
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Based on the reported evidences that DOT1L recruitment by fusion 
proteins is pivotal for leukemogenesis induced by MLL fusion oncogenes, we 
hypothesize that targeting the AF9/ENL-DOT1L protein-protein interaction 
represents an attractive and promising therapeutic strategy for several reasons. 
First, the interactions between MLL fusion protein and DOT1L were shown to be 
crucial for MLL transformation, since disruption of the interaction by mutations or 
deletion abolished transformation [2, 3, 10]. Second, since DOT1L has been 
involved in multiple biological processes [6], targeting the enzymatic activity of 
DOT1L might cause  hematopoietic and other toxicities. However, targeting 
AF9/ENL-DOT1L PPI is providing selective inhibition of the DOT1L activity and 
might avoid the side effects caused by global inhibition of DOT1L enzymatic 
activity. Third, as demonstrated by our work, DOT1L binds to AF9/ENL with a 
binding affinity of nanomolar range (Figure 2.4). AF9/ENL-DOT1L interaction is 
primarily mediated by a 10 amino acids region in DOT1L (Figure 2.6), and four 
hydrophobic residues are most crucial for the interaction (Figure 2.8), making the 
design of small molecule inhibitors a plausible reality. Development of small 
molecule inhibitors of the PPI between DOT1L and MLL-fusion proteins, AF9 and 
ENL, will help to address some of the mechanistic questions about the molecular 
interactions between MLL fusions, DOT1L and chromatin modifications.   
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4.2 Summary and conclusions of our work 
4.2.1 Characterization of AF9/ENL-DOT1L protein-protein interaction 
In Chapter 2, we have initiated the efforts of characterization of the 
protein-protein interaction between DOT1L and MLL-fusion proteins, AF9 and 
ENL. We have determined that the binding affinities between the full length 
DOT1L and AF9/ENL are 33 nM and 206 nM respectively. The binding site in 
DOT1L was mapped as the region corresponding to DOT1L 865LPISIPLSTV874. 
Our in vitro and in vivo findings demonstrated that the corresponding synthetic 
DOT1L 10mer peptide can competitively interfere with the interaction between 
MLL-fusion proteins, AF9 and ENL, and DOT1L. The alanine scanning 
mutagenesis studies showed the critical importance of several conserved 
hydrophobic residues, L865, I867, I869 and L871, for binding to AF9 and ENL. 
Deletion binding studies and HSQC NMR showed that an intact C-terminal 
domain in MLL-fusion proteins is critical for optimal interaction and binding of 
DOT1L 10-mer peptide to ENL protein induced significant conformation change 
of the protein. Furthermore, ENL mutant, L550E, which was reported to block the 
transforming capacity of MLL-ENL fusion protein [3], completely lost its ability to 
interact with DOT1L 10mer peptide.  
4.2.2 Validation of MLL fusion protein and DOT1L PPI as a therapeutic target  
Our functional studies using a colony forming unit assay provide strong 
evidence that the identified DOT1L865-874 fragment is essential for the DOT1L 
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recruitment and MLL-AF9 leukemic transformation. The colony forming potential 
of the MLL-AF9 immortalized cells was completely abolished by introduction of a 
DOT1L construct lacking the 10 amino acid AF9 interacting residues. In addition 
to the importance of the H3K79 methylation, these results highlight the the 
DOT1L recruitment and its interaction with MLL-AF9 is necessary for the 
transforming activity of this MLL fusion oncogene and validate that MLL fusion 
protein and DOT1L interaction as a potential therapeutic target. 
1.2.3 Phoshorylation of Ser 868 disrupts PPI between DOT1L and MLL-
fusion protein 
As an important post-transcription modification, phosphorylation is widely 
involved in the regulation of protein-protein interactions by affecting the stability, 
kinetics and specificity of interactions [11]. Phosphorylation and acetylation have 
been reported in DOT1L protein (http://www.phosphosite.org). However there are 
no reports of any PTMs in AF9 binding region of DOT1L. 
The identified AF9 binding region in DOT1L has two Serines and one 
Threonine which can be post translational modified. Therefore we investigated if 
phosphorylation of these residues will affect the binding of DOT1L to AF9 and 
ENL. Our results showed that only phosphorylation of DOT1L Ser 868 abolished 
the AF9-DOT1L interaction, while phosphorylation of Ser 872 and Thr 873 did not 
have a significant impact on the binding affinity. Knowing that the 
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phosphorylation has an important role in creating docking sites for interaction 
with other proteins, our findings indicate that phosphorylation of Ser 868 may 
allow transient and reversible regulation of the PPI between DOT1L and 
AF9/ENL, thus controlling the DOT1L recruitment.  
 
4.2.3 Development and optimization of FP assay and perform high-
throughput screening 
We designed a FP-based competitive assay, using fluorescein labeled 
DOT1L peptide including the 10 amino acids crucial for interaction with AF9 and 
ENL and recombinant GB1-AF9 protein. Various factors, including concentration 
of the probe and protein, percent of DMSO, time window for the assay reading, 
were tested to optimize the performance of the assay. The FP-based competitive 
assay was optimized and miniaturize to 384-well and 1536-well plate format with 
Z‟ factor of 0.75 and 0.65 respectively. To complement our FP assay, we also 
developed a SPR-based competitive assay and STD NMR as secondary assays 
to confirm and validate identified compounds from the HTS for their binding 
affinity and direct interactions with the fusion protein.  In addition the SPR based 
binding assay allowed us to further validate if the compounds can disrupt PPI 
since in our experimental setting DOT1L protein (826-1095) was immobilized on 
the chip and AF9 pre-incubated with tested compounds was injected over DOT1L. 
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Using the optimized FP assay, we applied high throughput screening approach to 
identify inhibitors of the PPI between DOT1L and AF9. Approximately 101,000 
compounds were screened at single concentration of 20 µM in 384-well plates. 
Total of 1191 compounds with inhibition larger than 3 fold of standard deviation 
(3SD) in primary screening were selected for confirmation assay in order to 
confirm their specific binding and eliminate fluorescent compounds, quenchers 
and compounds with reactive functional groups. Total of 164 compounds were 
selected and tested in dose-response screen.  Thirty nine compounds 
demonstrated dose-dependent inhibition in the FP assay. The analysis of the 
chemical structures of these 39 compounds showed that they can be classified 
into five clusters with different chemical scaffolds and the rest of the compounds 
have unique structures. Based on the potency, chemical structure and availability, 
eight compounds were purchased and retested by the FP competitive assay. 
Four compounds were confirmed in both FP and SPR competitive assay, with 
IC50 from 10 - 60 µM in FP assay, and 20 - 70µM in SPR assay respectively. The 
direct binding of two compounds, belonging to two different chemical classes, 
was further confirmed by STD NMR spectroscopy. These identified compounds 
merit further characterization and would serve as starting point for chemical 
optimizations and development of small molecule inhibitors targeting the AF9-
DOT1L interaction. 
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In summary, several candidate small molecules, with diverse chemical 
structure, were identified and validated that compete with binding of DOT1L to 
AF9/ENL. For the first time we have shown that it is possible to discover non-
peptide small-molecules that can block the interaction between DOT1L and AF9. 
This is an important initial proof-of-concept for the development of small 
molecules targeting C-terminal hydrophobic domain in AF9, indicating it is a 
“druggable” target. 
Overall, in the thesis described here, to gain insights into the unique 
functions of DOT1L in MLL-driven leukemia we have characterized AF9/ENL and 
DOT1L interaction and mapped the binding site to a short segment of 10 amino 
acids in DOT1L. Peptides derived from this region disrupted the interaction 
between DOT1L and MLL-AF9. DOT1L mutants lacking these 10 residues did 
not support transformation by MLL-AF9/ENL, while preserving global H3K79 
methylation. Based on these results, FP-based competitive assay was optimized 
and high-throughput screen of a large chemical library (>101,000 compounds) 
was performed. Several candidate small molecules, with diverse chemical 
structure, were identified and validated that compete with binding of DOT1L to 
AF9/ENL. These work generated sufficient data and evidence for further 
optimization of identified lead compounds based on structural analysis, chemical 
synthesis and cell based assays towards development of small molecule 
inhibitors targeting the PPI between MLL fusion proteins and DOT1L.  
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4.3 Future Directions 
The work presented in this thesis opens many potential avenues for future 
research toward further elucidating and understanding the mechanism of DOT1L 
recruitment by MLL fusion proteins and development of small molecules 
inhibitors of this PPI. Thus for the future directions of our work, we propose four 
major branches of research: 1) Following up the identified compounds from HTS; 
2) Development of peptidomimetic inhibitors; 3) Structural studies of AF9/ENL-
DOT1L interaction by X-ray crystallography. 4) Investigation the role of signal 
transduction in the regulation of DOT1L recruitment 
4.3.1 HTS hits follow up  
Our work identified several chemical scaffolds as inhibitors of the 
interaction between DOT1L and AF9 and generated sufficient data and evidence 
for their further optimization. Based on structural analysis of the most promising 
identified lead compounds, 36 and 38, in the first step commercially available 
analogues of these compounds will be ordered and tested by our established 
assays in order to be established initial structure activity relationship (SAR). The 
ultimate goal of these studies will be improving their potency and their further 
characterization in cell-based assays. 
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According to SciFinder database search, there are 42 and 30 analogues 
of compounds 36 and 38, respectively, with 80% or higher structure similarity. 
STD NMR studies of compound 36, identified class IV, indicated that the R1 
substitution is involved in interaction with AF9 protein. Therefore, commercially 
available compounds with variations on R1 substitution will be prioritized and 
ordered for establishment of initial SAR analysis. For compound 38, which 
belong to class I, in the initial step we will order commercially available 
analogues maintain the 1, 4-diazepin core structure, with variations on R 
substitutions. All purchased analogues will be tested by several binding assays 
including FP and SPR based competitive assay, ITC or direct SPR based binding 
assay, followed by STD and HSQC NMR spectroscopy. These assays will 
provide us with detailed information about their binding affinity to ENL and AF9, 
ability to disrupt the PPI and structural insights about the interactions between 
the small-molecule inhibitors and fusion proteins, AF9 and ENL. In addition, the 
physico-chemical properties, solubility as well as the metabolic stability will be 
used as criteria to select the most promising lead compound for further 
development.  
  
Based on the initial SAR analysis of the small set of compounds, 
additional medicinal chemistry efforts will be put to improve the potency and 
properties of these compounds. Developed compounds will be used as chemical 
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probes to understand the biological consequence of inhibiting DOT1L recruitment 
by MLL-fusion proteins, AF9 and ENL, and its impact on leukemia development, 
as well as on normal hematopoiesis. Ultimately, this work may result in the 
development of novel drugs for effective treatment of MLL acute leukemias. 
 
4.3.2 Development of peptidomimetics 
In addition to using HTS approach to identify small molecule inhibitors, 
based on our homology model of ENL/DOT1L 7mer peptide complex (Figure 
2.11) we will proceed towards developing peptidomimetics inhibitors as additional 
approach for targeting AF9/ENL-DOT1L interaction. This approach has been 
applied successfully in targeting protein-protein interactions [12, 13]. Based on 
our alanine scanning mutagenesis, four conserved hydrophobic residues in 
DOT1L were identified crucial for the interaction with AF9/ENL. As a starting 
point, we will synthesize series of mutated DOT1L peptides where these crucial 
residues will be substituted with un-natural amino acids in order to improve their 
binding affinity as well as proteolytic stability. For example, Homoleucine (Hle), 
Norleucine (Nle) and t-butyl-Leucine (Tle) can be used for Leucine and 
Isoleucine mutated peptides. In the next step using available structural 
information and the presence of two prolines in the binding peptide motif we will 
design constrain peptidomimetics which will have significant improvement of 
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physicochemical properties. This approach has been successfully used for 
developing Smac peptidomimetics [14]. Besides improving the hydrophobic 
interactions, future studies will be also focused on exploring the hydrogen bond 
interactions which were identified based on our homology model. It is known that 
hydrogen bonds between polarized atoms play a crucial role in protein 
interactions and therefore we are expecting that hydrogen bond interactions 
between the small-molecule inhibitors and the target protein will introduce both 
specificity and affinity within the hydrophobic ligand pocket.   
 
4.3.3 Protein crystallography studies 
We have already initiated protein crystallography studies based on our 
biochemical characterization of AF9/ENL and DOT1L interactions. A series of 
AF9/ENL-DOT1L fusion protein constructs were generated (Appendix 1, Figure 1) 
and these constructs gave good expression of soluble fusion proteins (Appendix 
1, Figure 2). Once we optimized the purification of these recombinant fusion 
proteins, we will set up crystallization screening trials using the following buffer 
screens: Hampton Index, Hampton Screen, JCSG and Emerald Wizards. 
Positive hits from the initial screens will be optimized by grid screen to get good 
quality protein crystals suitable for structure determination. If the initial 
crystallization screening trials fail to generate positive hits, NMR spectroscopy 
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can be applied as an alternative approach. These generated constructs can be 
used to express 15N and 13C labeled proteins suitable for NMR structural studies. 
With the combination of X-ray crystallography and NMR approaches, we would 
have better understanding of this protein-protein interaction from the structure 
perspective. 
 
4.3.4 Role of post-transcriptional modification in regulation of DOT1L 
recruitment by MLL fusion proteins 
The increase in complexity from the level of the genome to the proteome 
is further facilitated by protein post-translational modifications (PTMs). PTMs are 
chemical modifications that play a key role in functional proteomics, because 
they regulate activity, localization and interaction with other cellular molecules 
such as proteins, nucleic acids, lipids, and cofactors. These modifications include 
phosphorylation, glycosylation, ubiquitination, nitrosylation, methylation, 
acetylation, lipidation and proteolysis and influence almost all aspects of normal 
cell biology and pathogenesis. Therefore, identifying and understanding PTMs is 
critical in the study of cell biology and disease treatment and prevention.  
Our results indicate that phosphorylation within the consensus AF9 
binding sequence in DOT1L, Ser 868, abolishes the AF9-DOT1L interaction and 
therefore this phosphorylation may allow transient and reversible regulation of 
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the PPI between DOT1L and AF9/ENL. Thus it is very important these studies to 
be continued towards identification of phosphorylated S868 in vivo, followed by 
determination of the proteins/pathways that mediate this phosphorylation. 
Recent technical developments in large–scale mass spectrometry-based 
phosphoproteomic analysis have demonstrated the powerful potential for rapid 
discovery of phosphorylation-site in proteins. Metal oxide affinity chromatography 
(MOAC) followed by immunoprecipitation using phopshoserine antibodies to 
enrich for phosphoserine peptides followed by standard LC-MS/MS analysis is 
one of the methods for large scale identification of phosphopeptides and 
phosphorylation sites.  
Generating antibody which can specifically recognize the phosphorylation 
of S868 can be used for profiling panel of cell lines which will provide insights 
about the phosphorylation status of endogenous DOT1L protein in different type 
of normal as well as cancer cell lines.  
Using available web based programs and the identified binding sequence 
of 10 amino acids in DOT1L protein, it was predicted that this region might be a 
possible substrate motif of several Ser/Thr kinases, including Glycogen synthase 
kinase 3 (GSK-3), G protein-coupled receptor kinase 1 (GRK-1), MAPKAPK2 
kinase and PKA kinase. In order to be determined which Ser/Thr kinase is 
responsible for Ser 868 modification, different DOT1L synthetic peptides, wild 
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type and mutated, can be used as a substrate and screen a panel of Ser/Thr 
kinases.   
Apart from changing the intrinsic properties of proteins, an important role 
of phosphorylation is to create docking sites which mediate the protein-protein 
interactions. Therefore, to study the potential role of DOT1L phosphorylation for 
interaction with other proteins besides with MLL-fusion proteins, pull down assay 
using the S868 phosphorylated peptide can be applied. Cellular proteins which 
might interact with this peptide and be pulled down can be identified by MS. 
The significance of these future studies is the elucidation if the post-
translational modifications are involved in regulation of the recruitment of DOT1L 
by MLL-fusion proteins, which may allow transient and reversible regulation of 
these interactions. Furthermore, identifying signaling network involved in DOT1L 
phosphorylation in the AF9 binding motif might open new potential therapeutic 
intervention.   
Overall, our targeted molecular approach to prevent DOT1L recruitment to 
MLL fusion proteins without blocking normal DOT1L functions represents a major 
innovation of this study. By taking different approaches we expect to identify and 
develop both small molecule and peptidomimetics inhibitors of the DOT1L/ MLL-
fusion protein interaction. Inhibitors that will achieve this goal could markedly 
improve the therapeutic window of DOT1L inhibitors in patients with MLL-driven 
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acute myeloid and lymphoblastic leukemia, which are currently incurable and 
there is a clinical need of novel therapeutics. 
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Appendices 
Appendix 1. Design and expression of DOT1L-AF9 and DOT1L-ENL fusion 
proteins for structural studies 
Background 
During our initial efforts to express and purify the AF9/ENL C-terminal 
domain, we found that the untagged AF9 (497-568) or ENL (489-559) expressed 
in Escherichia coli as insoluble inclusion bodies (Figure A.1). Although AF9 or 
ENL C-terminal domain cleaved from the MBP- or GB1-fusion did retain DOT1L 
protein and peptide-binding activity and we were able to use the cleaved protein 
to perform biochemical binding assays, these proteins were of insufficient purity 
and biochemical homogeneity for use in biophysical studies, especially for 
crystallography studies. Recently, the NMR structure of AF4-AF9 fusion protein 
was published [1]. In this study, a construct, which includes 43 amino acids of 
AF4 fused to the flexible residues immediately preceding the AF9 C-terminal 
domain, was generated to overcome the poor solubility of AF9 protein. This 
approach resulted in expression of a monomeric homogeneous complex and 
yielded high quality spectra suitable for structure determination. According to the 
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NMR structural studies, the hydrophobic core of AF9 is not sufficient  to maintain 
an independently folded structure. The AF9 CTD need to recruit partners through 
coupled folding and binding to form a well folded complex. This is also observed 
in ENL C-terminal domain by our HSQC NMR results. Binding of DOT1L protein 
or peptides to ENL induced significant conformational change of ENL protein and 
indicated formation of a folded complex structure (Figure 2.10). Based on these 
studies, we decided to design DOT1L-AF9 and DOT1L-ENL fusion proteins for 
the further biophysical studies. The design of the fusion protein was based on 
these criteria: 1) including the minimum interaction region of DOT1L and 
AF9/ENL; 2) including a flexible linker between two proteins, to allow for optimum 
folding and formation of the protein complex.  
Material and methods 
Molecular cloning 
The genes sequences for the fusion proteins were based on the protein 
sequences and the codons were optimized for E. coli expression. All the genes 
were synthesized by Integrated DNA Technologies. All the constructs for fusion 
protein expression were cloned by ligation independent cloning (LIC) methods as 
described before [2]. The primers for PCR are listed in Table 1 and synthesized 
by Life Technologies. Different fusion constructs (Figure 1) were cloned into 
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Table 1 Primers for molecular cloning 
Fusion protein No.  Sequence (5‟-3‟) 
1 Sense TACTTCCAATCCAATGCAGGA AGC AGT GGC 
Antisense TTATCCACTT CCATTA GCT CGTACCGCTGGTCT 
2 Sense TACTTCCAATCCAATGCAGGATCTTCAGGC 
Antisense TTATCCACTTCCATTATGAGGTACCGCTGGTCT 
3 Sense TACTTCCAATCCAATGCAGGGAGTAGTGGC 
Antisense TTATCCACTTCCATTAGGTTGCCACTGCTTCCA 
 
pMCSG7-LIC vector. All the constructs were sequenced by The University of 
Michigan Sequencing Core. 
Protein expression analysis 
All the recombinant proteins were expressed in Escherichia coli strain 
BL21 (DE3) (Invitrogen) in a small scale (50 mL) as a primary screening. The 
medium for bacterial growth was Terrific Borth (TB). All the proteins were 
induced with 200 µM IPTG at 16 °C for 20 h. The cells were harvested after 20h 
and re-suspended in cold lysis buffer (50 mM Tris HCl, pH 7.5, 150 mM NaCl, 
0.01 % β-mercatoethanol) and lysed by sonication. The cells were centrifuged at 
13,200 rpm for 15 min. The whole cell lysate before centrifugation, the 
supernatant and pellet after centrifuge were loaded on SDS-PAGE for analysis.  
Results and Discussion 
Design of DOT1L-AF9 and DOT1L-ENL fusion proteins 
  
146 
 
 
 
Figure 1 Design of DOT1L-AF9 and DOT1L-ENL fusion 
proteins. His-tag and TEV cleavage site were on the N-
terminus of the protein, following with DOT1L (856-897) or 
DOT1L (856-883). The AF9 (490-568) or ENL (482-559) 
was on the C-terminus and there is a three residue (PAG) 
linker between DOT1 L and AF9 or ENL.   
The designed fusion proteins are illustrated in Figure A.1. We chose to the 
include AF9 (490-568) or ENL (482-559) on the C-terminus of the fusion protein. 
Based on the published NMR structure of AF4-AF9 fusion protein, two different 
DOT1L fragments 
were chosen as the N-
terminus of the fusion 
protein, they are: 
DOT1L 856-897 and 
DOT1L 856-883.Both 
of these two 
fragments contain the 
AF9/ENL interaction 
region. A three 
residues linker 
including PAG was introduced between the two proteins.  
 
Expression of DOT1L-AF9/ENL fusion proteins 
The expression of the designed DOT1L-AF9 or DOT1L-ENL fusion 
proteins was tested in a small scale. After induction with 200 µM IPTG at 16 °C 
for 20 h, the cells were analyzed by SDS-PAGE. As shown Figure 2A, His-ENL 
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Figure 2 (A) Expression of His-ENL (489-559) in E. coli BL21 (DE3) cells as 
monitored by Glycine-SDS-polyacrylamide gel electrophoresis of cell extracts. 
Lane1, protein ladder; lane 2, non-induced; lane 3, induced with IPTG, total 
extract; lane 4, induced with IPTG, supernatant; lane 5, induced with IPTG, 
pellet. The calculated molecular weight of His-ENL (489-559) is 11.1 kDa. (B) 
Expression of DOT1L-AF9/ENL fusion proteins in in E. coli BL21 (DE3) cells. 
Lane 1, protein ladder; lane 2, empty; lane 3, fusion protein 1, induced with 
IPTG, supernatant; lane 4, empty; lane 5, fusion protein 2, induced with IPTG, 
supernatant; lane 6, empty; lane 7, fusion protein 3, induced with IPTG, 
supernatant. The calculated molecular weight of fusion protein 1, 2 and 3 are: 
16.5kDa, 14.6kDa, 16.3kDa respectively. 
(489-559) protein was not soluble when expressed alone (Figure A.2A, lane 5). 
However, the DOT1L-AF9 and DOT1L-ENL fusion proteins (Figure A.2B, lane 3, 
5 and 7), were soluble after the IPTG induction.   
The expression of the DOT1L-AF9/ENL fusion protein in the soluble 
fraction of the cell lysate indicates that fusion of DOT1L to AF9 and ENL assist 
the folding and solubility of the disordered protein. With  further expression and 
purification of the fusion protein, the protein can be applied for biophysical 
structural studies.  
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Appendix 2 SPR Sensorgrams representing the concentration-dependent 
binding of AF9 (497 - 568) and ENL (489 - 559) proteins tested with of truncated 
constructs of DOT1L  
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Appendix 3 Peptide sequence and IC50 values of wild type and alanine mutated 
DOT1L peptides against AF9 and ENL proteins obtained by competitive SPR 
based assay using CM5 chip with immobilized DOT1L protein. 
Name Sequence 
 
IC50 ± SD [µM] 
AF9 ENL 
DOT1L 
10mer 
Ac-LPISIPLSTV-NH2 
( a.a. 865-874 ) 
0.49 ± 0.22 1.34 ± 0.34 
L865A Ac-APISIPLSTV-NH2 98.5 ± 15.1 27.5 ± 6.8 
P866A Ac-LAISIPLSTV-NH2 3.3 ± 0.6 6.5 ± 1.2 
I867A Ac-LPASIPLSTV-NH2 57.2 ± 17.3 >200 
S868A Ac-LPIAIPLSTV-NH2 5.3 ± 1.7 29.1 ± 0.8 
I869A Ac-LPISAPLSTV-NH2 >200 >200 
P870A Ac-LPISIALSTV-NH2 2.8 ± 0.1 11.6 ± 1.7 
L871A Ac-LPISIPASTV-NH2 30.7 ± 10.3 146.8 ± 11.5 
S872A Ac-LPISIPLATV-NH2 0.55 ± 0.21 2.8 ± 0.6 
T873A Ac-LPISIPLSAV-NH2 0.058 ± 0.017 0.36 ± 0.02 
V874A Ac-LPISIPLSTA-NH2 0.7 ± 0.02 4.2 ± 0.6 
DOT1L 7mer Ac-LPISIPL-NH2 3.9 ± 0.1 7.3 ± 0.3 
DOT1L 
16mer 
Ac-LPISIPLSTVQPNKLP-NH2 (a.a. 
865 - 880) 
0.32 ± 0.01 1.56 ± 0.09 
AF4 14mer Ac- LMVKITLDLLSRIP-NH2 (a.a. 
760 - 773) 
0.20 ± 0.06 0.43 ± 0.15 
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Appendix 4 Identified peptides from Flag-DOT1L by mass spectrometry. The 
phosphorylated Serine, Threonine or Tyrosine residues are highlighted in bold 
and indicated as pS, pT or pY. 
Protein Peptide sequence Initial 
probability 
Phosphorylate
d sites in  
DOT1L 
(Q8TEK3) 
sp|Q8TEK3 AIDSIHQLWK 0.999  
sp|Q8TEK3 ALTYNDLIQAQK 0.999  
sp|Q8TEK3 CEELQLDWATLSLEK 0.999  
sp|Q8TEK3 EAGEGGLPLCGPTDK 0.999  
sp|Q8TEK3 GDLPSDSGFpSDPESEAK 0.999 S1035 
sp|Q8TEK3 GDLPSDSGFSDPESEAK 0.999  
sp|Q8TEK3 GPEAAGLSpSPLSFPSQR 0.999 S1349 
sp|Q8TEK3 GPEAAGLSSPLSFPSQR 0.999  
sp|Q8TEK3 GSVSWTGKPVSYYLHTIDR 0.999  
sp|Q8TEK3 HAEYTLER 0.999  
sp|Q8TEK3 HHDAAHEIIETIR 0.999  
sp|Q8TEK3 HILQQVYNHSVTDPEK 0.999  
sp|Q8TEK3 IANTSVIFVNNFAFGPEVDHQLK 0.999  
sp|Q8TEK3 IQYLQFLAYTK 0.999  
sp|Q8TEK3 IVFTITTGAGSAK 0.999  
sp|Q8TEK3 KIATISLESK 0.999  
sp|Q8TEK3 KNQTALDALHAQTVSQTAASSPQDAYR 0.999  
sp|Q8TEK3 LAMENYVLIDYDTK 0.999  
sp|Q8TEK3 LGGAAQGPLPEASK 0.999  
sp|Q8TEK3 LKSPVGAEPAVYPWPLPVYDK 0.999  
sp|Q8TEK3 LPVSIPLASVVLPSR 0.999  
sp|Q8TEK3 LSPQDPRPLpSPGALQLAGEK 0.999 S834 
sp|Q8TEK3
-2 
LTNSHAMGSFSGVAGGTVGGN 0.999  
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sp|Q8TEK3 NAQLLGAAQQLLSHCQAQK 0.999  
sp|Q8TEK3 NGHNLFISAAAVPPGSLLSGPGLA 
PAASSAGGAASSAQTHR 
0.999  
sp|Q8TEK3 NSLPApSPAHQLSSpSPR 0.999 S1001, S1009 
sp|Q8TEK3 NSLPASPAHQLSSpSPR 0.999 S1009 
sp|Q8TEK3 NSLPASPAHQLSSSPR 0.999  
sp|Q8TEK3 Q[111]IGANAHGAGSR 0.999  
sp|Q8TEK3 pSSPVPYQDHDQPPVLK 0.999 S1152 
sp|Q8TEK3 SADSPLQASSALSQNSLFTFRPALEEPSADAK 0.999  
sp|Q8TEK3 SCVPPDDALSLHLR 0.999  
sp|Q8TEK3 SPHSPFYQLPPSVQR 0.999  
sp|Q8TEK3 SPVGAEPAVYPWPLPVYDK 0.999  
sp|Q8TEK3 SSPVPYQDHDQPPVLK 0.999  
sp|Q8TEK3 SSTPQHPLLLAQPR 0.999  
sp|Q8TEK3 STFSPISDIGLAK 0.999  
sp|Q8TEK3 VAGPADAPMDpSGAEEEK 0.999 S374 
sp|Q8TEK3 VAGPADAPMDSGAEEEK 0.999  
sp|Q8TEK3 GKEGSDANPFLSK 0.9989  
sp|Q8TEK3 IVSSKPFAPLNFR 0.9989  
sp|Q8TEK3 LSGLAAPDYTR 0.9989  
sp|Q8TEK3 NLSDIGTIMR 0.9989  
sp|Q8TEK3 NQTALDALHAQTVSQTAASSPQDAYR 0.9989  
sp|Q8TEK3 TILENYFSSLK 0.9989  
sp|Q8TEK3 WVCEEIPDLK 0.9989  
sp|Q8TEK3 ASAGTPSLSAGVpSPK 0.9988 S1104 
sp|Q8TEK3 LGGAAQGPLPEASKGDLPSDSGFSDPESEAK 0.9988  
sp|Q8TEK3 RASAGTPSLSAGVpSPK 0.9988 S1104 
sp|Q8TEK3 HLSQDHTVPGRPAASELHSR 0.9987  
sp|Q8TEK3 GDFLSEEWR 0.9986  
sp|Q8TEK3 EQSEQLEQDNR 0.9983  
sp|Q8TEK3 QNTPQYLASPLDQEVVPCTPSHVGRPR 0.9983  
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sp|Q8TEK3 ASLQELLGQEK 0.9981  
sp|Q8TEK3 NSLPApSPAHQLpSSSPR 0.9981 S1001, S1007 
sp|Q8TEK3 KPAPAGEPVNSSK 0.998  
sp|Q8TEK3 QLDGLAGLKGEGSR 0.9979  
sp|Q8TEK3 ASAGTPSLSAGVSPK 0.9978  
sp|Q8TEK3 ENGLPYQSPSVPGSMK 0.9978  
sp|Q8TEK3 ENGLPYQSPSVPGSMK 0.9963  
sp|Q8TEK3 AYGSSGELITSLPISIPLSTVQPNK 0.9962  
sp|Q8TEK3 HCLELQISIVELEK 0.9953  
sp|Q8TEK3 LHLELDCTK 0.9952  
sp|Q8TEK3 TILENYFSSLKNPK 0.993  
sp|Q8TEK3 LNTRPSTGLLR 0.9855  
sp|Q8TEK3 ENGLPYQSPSVPGSMK 0.9833  
sp|Q8TEK3 GKEAGEGGLPLCGPTDK 0.9831  
sp|Q8TEK3 EISAHNQQLR 0.9805  
sp|Q8TEK3 HLpSQDHTVPGRPAASELHSR 0.9801 S786 
sp|Q8TEK3 LSGLAAPDYTRLpSPAK 0.9801 S775 
sp|Q8TEK3 ENGLPYQSPSVPGSMK 0.9752  
sp|Q8TEK3 IATISLESK 0.9748  
sp|Q8TEK3 STPSPVLQPR 0.9738  
sp|Q8TEK3 KIATISLESKpSPPK 0.9721 S1213 
sp|Q8TEK3 KHAEYTLER 0.9689  
sp|Q8TEK3 STPpSPVLQPR 0.9669 S902 
sp|Q8TEK3 HSPNPLLVAPTPPALQK 0.9605  
sp|Q8TEK3 QLDGLAGLK 0.9497  
sp|Q8TEK3 HSPLTASAR 0.9484  
sp|Q8TEK3 RASAGTPSLSAGVSPK 0.9442  
sp|Q8TEK3 QLDGLAGLK 0.8468  
sp|Q8TEK3 IATISLESKpSPPK 0.8465 S1213 
sp|Q8TEK3 SpTPpSPVLQPR 0.8444 T900, S902 
sp|Q8TEK3 HLSQDHTVPGRPAApSELHSR 0.7725  
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sp|Q8TEK3 SFESMQR 0.7724  
sp|Q8TEK3 ELEPDASR 0.7695  
sp|Q8TEK3 VVELSPLK 0.7199  
sp|Q8TEK3 VVELpSPLK 0.6456 S297 
sp|Q8TEK3 ARSpTPpSPVLQPR 0.6223 T900, S902 
sp|Q8TEK3 LREEQEAAR 0.5131  
sp|Q8TEK3 LSGLAAPDpYTRLSPAK 0.441 Y771 
sp|Q8TEK3 QQELLQLK 0.3865  
sp|Q8TEK3 TLENGGGLAGR 0.2253  
sp|Q8TEK3 LNNYEPFSPEVYGETSFDLVAQM[147]IDEIK 0.1867  
sp|Q8TEK3 IATISLEpSKSPPKTLENGGGLAGR 0.0994 S1211 
sp|Q8TEK3 pSPPKTLENGGGLAGR 0.0716 S1213 
sp|Q8TEK3 AEHTKENGLPYQSPSVPGSMK 0.0683  
sp|Q8TEK3 VAGPADAPMDpSGAEEEKAGAATVK 0.0644 S374 
 
 
  
155 
 
 
 
A.CD of AF9(497-568) and ENL (489-559) protein. B. CD of different DOT1L 
peptides. DOT1L peptides were dissolved in phosphate buffer (50mM Na2HPO4, pH 
7.4, 100mM NaCl). ENL and AF9 protein were dialyzed against the above 
phosphate buffer overnight. CD measurements were performed at room 
temperature using a Jasco J-715 and a quartz flow cell with a 1 mm path length. 
The spectra were averaged over 10 scans and the baseline (buffer scan) was 
subtracted from each spectrum.  
 
Appendix 5 Circular dichroism of proteins and peptides.  
 
 
 
